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A B S T R A C T
Background
Previous research has shown that the prophylactic use of uterotonic agents in the third stage of labour reduces postpartum blood loss
and moderate to severe postpartum haemorrhage (PPH). PPH is defined as a blood loss of 500 mL or more within 24 hours after birth.
This is one of a series of systematic reviews assessing the effects of prophylactic use of uterotonic drugs; in this review prophylactic
ergot alkaloids as a whole, and different regimens of administration of ergot alkaloids, are compared with no uterotonic agents. This is
an update of a Cochrane Review which was first published in 2007 and last updated in 2011.
Objectives
To determine the effectiveness and safety of prophylactic use of ergot alkaloids in the third stage of labour by any route (intravenous
(IV), intramuscular (IM), or oral) compared with no uterotonic agents, for the prevention of PPH.
Search methods
For this update, we searched theCochrane Pregnancy and ChildbirthGroup’s Trials Register, ClinicalTrials.gov, theWHO International
Clinical Trials Registry Platform (ICTRP) (19 September 2017); we also searched reference lists of retrieved studies.
Selection criteria
We included all randomised controlled trials or cluster-randomised trials comparing prophylactic ergot alkaloids by any route (IV, IM,
or oral) with no uterotonic agents in the third stage of labour among women giving birth vaginally.
Data collection and analysis
Two review authors independently assessed trials for inclusion, extracted data and checked them for accuracy; they also assessed the
risk of bias in included studies. Two review authors assessed the quality of the evidence using the GRADE approach.
Main results
There were eight included studies: three studies had a low risk of bias and five studies had high risk of bias. The studies compared ergot
alkaloids with no uterotonic agents, with a total of 2031 women in the ergot alkaloids group and 1978 women in the placebo or no
treatment group. Seven studies used the IV/IM route of administration and one study used the oral route.
Ergot alkaloids (any route of administration) versus no uterotonic agents
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Use of ergot alkaloids in the third stage of labour decreasedmean blood loss (mean difference (MD) -80.52 mL, 95% confidence interval
(CI) -96.39 to -64.65 mL; women = 2718; studies = 3; moderate-quality evidence); decreased PPH of at least 500 mL (average risk
ratio (RR) 0.52, 95% CI 0.28 to 0.94; women = 3708; studies = 5; I2 = 83%; low-quality evidence); increased maternal haemoglobin
concentration (g/dL) at 24 to 48 hours postpartum (MD 0.50 g/dL, 95% CI 0.38 to 0.62; women = 1429; studies = 1; moderate-
quality evidence); and decreased the use of therapeutic uterotonics (average RR 0.37, 95% CI 0.15 to 0.90; women = 2698; studies
= 3; I2 = 89%; low-quality evidence). There were no clear differences between groups in severe PPH of at least 1000 mL (average RR
0.32, 95% CI 0.04 to 2.59; women = 1718; studies = 2; I2 = 74%; very low-quality evidence). The risk of retained placenta or manual
removal of the placenta, or both, were inconsistent with high heterogeneity. Ergot alkaloids increased the risk of elevated blood pressure
(average RR 2.60, 95% CI 1.03 to 6.57: women = 2559; studies = 3; low-quality evidence) and pain after birth requiring analgesia
(RR 2.53, 95% CI 1.34 to 4.78: women = 1429; studies = 1; moderate-quality evidence) but there were no differences between groups
in vomiting, nausea, headache or eclamptic fit.
Results for IV/IM ergot alkaloids versus no uterotonic agents were similar to those for the main comparison of ergot alkaloids
administered by any route, since most of the studies (seven of eight) used the IV/IM route. Only one small study (289 women) compared
oral ergometrine with placebo and it showed no benefit of ergometrine over placebo. No maternal adverse effects were reported.
None of the studies reported on any of our prespecified neonatal outcomes
Authors’ conclusions
Prophylactic IM or IV injections of ergot alkaloids may be effective in reducing blood loss, reducing PPH (estimated blood loss of at
least 500 mL), and increasing maternal haemoglobin. Ergot alkaloids may also decrease the use of therapeutic uterotonics, but adverse
effects may include elevated blood pressure and pain after birth requiring analgesia. There were no differences between groups in terms
of other adverse effects (vomiting, nausea, headache or eclamptic fit). There is a lack of evidence on the effects of ergot alkaloids on
severe PPH, and retained or manual removal of placenta. There is also a lack of evidence on the oral route of administration of ergot
alkaloids.
P L A I N L A N G U A G E S U M M A R Y
Managing the end of childbirth (placenta delivery) with ergot alkaloid medications (e.g. ergometrine)
What is the issue?
The third stage of labour is the period from the birth of the baby to the expulsion of the placenta and membranes. As the placenta
separates, there is inevitably some blood loss from the placental site until the muscles of the uterus clamp the blood vessels. Fit, healthy
women cope with this normal blood loss without problems, but where poor nutrition, poor sanitation and limited or no access to
clinical care are complications of pregnancy, severe morbidity and death can result from excessive blood loss at birth. This is very
common in low- and middle-income countries. Active intervention, called ’active management of third stage’, is recommended for the
third stage of labour to reduce excess blood loss. Active intervention incorporates: 1) the administration of a uterotonic medication
(medicine that stimulates contractions), given just before or just after the baby is born to help the muscles of the uterus contract; 2) cord
clamping, performed approximately one to three minutes after birth; and 3) the use of controlled cord traction to deliver the placenta
in settings where skilled birth attendants are available. This review of studies looked at the use of one group of uterotonic medications
called ergot alkaloids (e.g. ergometrine) as part of this active management.
Why is this important?
A previous systematic review showed that the combination of ergometrine and oxytocin was associated with a significantly lower
postpartum haemorrhage (PPH) rate (defined as blood loss of at least 500 mL) but a greater incidence of side-effects compared to the
use of oxytocin alone. However, there was no review comparing ergometrine with no uterotonic medications and different routes or
timings of administration for the prevention of PPH.
What evidence did we find?
We searched for evidence in September 2017 and included eight trials involving 4009 women receiving ergometrine by mouth (orally),
into the muscle (intramuscularly (IM)) or into the vein (intravenously (IV)). Of eight trials, seven included studies were analysed in
this updated review.
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The evidence from the trials analysed suggests that ergot alkaloids may decrease mean blood loss, increase maternal haemoglobin levels
in the blood, and may decrease both blood loss of at least 500 mL (PPH) and the use of therapeutic uterotonics. It is uncertain whether
ergot alkaloids have any effect on numbers of women experiencing high blood loss of at least 1000 mL (severe PPH). The evidence
also suggested that they may increase adverse effects such as increased blood pressure and pain after birth. They may make little or no
difference between groups in terms of other adverse effects (vomiting, nausea, headache or eclamptic fit) and results were inconsistent
on the risk of retained or manual removal of placenta. Most of the evidence came from trials that administered ergot alkaloids using
the IM or IV route. There was only one small trial that looked at the use of oral ergot alkaloids and results were inconclusive. There
were limited numbers of included studies and results between studies were not always consistent or precise. Overall quality of evidence
across critical and important outcomes ranged from very low to moderate.
What does this mean?
The IV or IM route, although it may reduce blood loss and PPH, was associated with the adverse effects of raised blood pressure and
pain due to contractions of the uterus. There was not enough evidence on the oral route of administering ergot alkaloids. There are
other medications, namely oxytocin, syntometrine and prostaglandins (which are assessed in other Cochrane Reviews), that can be
used and may be preferable.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Ergot alkaloids (any route of administration) versus no uterotonic agents in the third stage of labour
Patient or population: women in the third stage of labour
Settings: hospital sett ings in the USA, Ireland, and the Netherlands
Intervention: ergot alkaloids (any route of administrat ion)
Comparison: no uterotonic agents
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Ergot alkaloids (any
routes) and no utero-
tonic agents
Mean blood loss (mL)
visual est imation
The mean blood loss
ranged across control
groups f rom 234.8 to
520 mL
The mean blood loss in
the intervent ion groups
was
80.52 mL lower
(96.39 to 64.65 lower)
2718
(3 studies)
⊕⊕⊕©
moderate1
PPH (estimated or
measured blood loss of
at least 500 mL)
visual est imation
Study population RR 0.52
(0.28 to 0.94)
3708
(5 studies)
⊕⊕©©
low1,2
118 per 1000 61 per 1000
(33 to 111)
Medium risk population
120 per 1000 62 per 1000
(34 to 113)
Severe PPH (estimated
or measured blood loss
of at least 1000 mL)
visual est imation
Study population RR 0.32
(0.04 to 2.59)
1718
(2 studies)
⊕©©©
very low 1,2,3
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31 per 1000 10 per 1000
(1 to 80)
Medium risk population
64 per 1000 20 per 1000
(3 to 166)
Maternal haemoglobin
concentration at 24 to
48 hours postpartum
(g/dL)
The mean maternal
haemoglobin concen-
trat ion at 24 to 48 hours
postpartum in the con-
trol group was 12.09 g/
dL
The mean maternal
haemoglobin concen-
trat ion at 24 to 48 hours
postpartum in the inter-
vent ion groups was
0.5 g/dL higher
(0.38 to 0.62 higher)
1429
(1 study)
⊕⊕⊕©1
moderate
Use of therapeutic
uterotonics
Study population RR 0.37
(0.15 to 0.9)
2698
(3 studies)
⊕⊕©©
low1,2
132 per 1000 49 per 1000
(20 to 119)
Medium risk population
129 per 1000 48 per 1000
(19 to 116)
Elevation of blood
pressure
Study population RR 2.6
(1.03 to 6.57)
2559
(3 studies)
⊕⊕©©
low 1,2
133 per 1000 346 per 1000
(137 to 874)
Medium risk population
120 per 1000 312 per 1000
(124 to 788)
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Pain after birth requir-
ing analgesia (not pre-
specified)
Study population RR 2.53
(1.34 to 4.78)
1429
(1 study)
⊕⊕⊕©1
moderate
18 per 1000 46 per 1000
(24 to 86)
Medium risk population
18 per 1000 46 per 1000
(24 to 86)
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval; RR: Risk rat io; PPH: postpartum haemorrhage;mL: m illi l it re; g/dL: grams per decilit re
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Lim itat ions in study design (-1)
2 Inconsistency of results, high I2 value (-1)
3 Wide conf idence interval crossing the line of no ef fect (-1)
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B A C K G R O U N D
Description of the condition
The third stage of labour is defined as the period of labour from
birth of the baby to the expulsion or extraction of the placenta
and membranes. Placental separation involves capillary haemor-
rhage and shearing of decidua spongiosa because of the mechani-
cal action of uterine contraction. Blood loss during the third stage
of labour depends on the time between placental separation and
contraction of the placental bed by uterine activity. Most women
experience mild to moderate blood loss. However, the third stage
of labour can be a potentially hazardous period of childbirth re-
sulting in postpartum haemorrhage (PPH). The World Health
Organization (WHO) defines PPH as blood loss after delivery of
500 mL or more (WHO 2000).
In 2015, the estimate of global maternal mortality was approxi-
mately 303,000 (WHO 2015). Almost all maternal deaths occur
in low- andmiddle-income countries. Unfortunately, due to socio-
economic conditions, dwindling investment in health, and non-
or poorly-functioning health systems, many women are unable to
access essential care during pregnancy, childbirth and the postpar-
tum period (Acuin 2010). The most common preventable causes
of maternal death are haemorrhage, pregnancy-induced hyperten-
sion and sepsis. One of themost common causes ofmaternal death
worldwide is PPH (Say 2014; McCormick 2002; WHO 2001).
Active management of the third stage of labour, before the occur-
rence of PPH, is better than treatment when blood loss is 500 mL
or more. The third stage of labour is an important and critical pe-
riod for interventions to reduce the incidence of PPH (De Groot
1995). Active management involves prophylactic use of oxytocic
drugs; umbilical cord clamping; and controlled cord traction for
delivery of the placenta (WHO 2003). Three recommendations
for active management in the third stage of labour are adminis-
tration of an uterotonic drug within one minute of the birth of
the baby, clamping and cutting the umbilical cord after birth, and
delivering the placenta by applying controlled cord traction dur-
ing a strong uterine contraction (Den Hertog 2001; McCormick
2002). Combined controlled cord traction in active management
of the third stage reduces the time of the third stage, the incidence
of PPH and retained placenta and the need for additional oxyto-
cic agents compared with using only uterotonic drugs (Brucker
2001). Recent WHO recommendation suggests late cord clamp-
ing, in which the umbilical cord is clamped approximately one
to three minutes after birth of the baby, and controlled cord trac-
tion is recommended in settings where skilled birth attendants are
available (WHO 2012). The recent updated Cochrane Review on
active management of the third stage of labour showed a reduc-
tion of the incidence of severe blood loss and blood transfusion
requirement but an increase in maternal blood pressure and pain,
as well as reducing the baby’s birthweight (Begley 2015). Likewise,
the updated Cochrane Review on controlled cord traction for the
third stage of labour found the reduction of blood loss and dura-
tion of the third stage of labour (Hofmeyr 2015).
Description of the intervention
Uterotonic agents are divided into three groups: ergot alkaloids,
oxytocin and prostaglandins (De Groot 1998; DenHertog 2001).
Their mechanisms of preventing PPH are different. Methyler-
gometrine is the most common type of ergot alkaloid; it increases
the muscle tone of the uterus, with superimposed fast rhythmic
contractions of the myometrium and tetanic contraction for sev-
eral hours resulting in compressed myometrial blood vessels. Oxy-
tocin acts through oxytocin receptors inmyometriumanddecidua,
leading to fast and long-lasting contractions upon basal tone of the
myometrium. Syntometrine, consisting of five units of oxytocin
and 0.5 mg of ergometrine, has been designed to take advantage
of the rapid onset of action of oxytocin, combined with the longer
action of ergometrine. Carbetocin is similar to oxytocin, but it has
a rapid onset and prolonged duration of action relative to oxy-
tocin. The effect of a room-temperature stable formulation of car-
betocin under the WHO CHAMPION Trial will be soon pub-
lished (Widmer 2016). Finally, prostaglandins induce strong my-
ometrial contractions by increasing uterine tone (DeGroot 1995).
There are several Cochrane systematic reviews already published
about the use of various uterotonic drugs in the third stage of
labour for preventing PPH (McDonald 2004; Su 2012; Tunçalp
2012; Westhoff 2013).
Recent studies have highlighted oxytocin as the first-line drug used
for prophylaxis based on the evidence of its benefit in terms of
reducing PPH compared with using no uterotonic drugs, and its
favourable side-effect profile (Westhoff 2013). However, the use
of the combination preparation of ergot alkaloid plus oxytocin,
syntometrine, is associated with a statistically significant reduction
of PPH when compared with oxytocin alone, attributable to the
ergometrine effect (McDonald 2004). Because of the effect of
strong and lasting uterine contractions, ergometrine has been used
as one of the uterotonic drugs of choice for preventing PPH.
How the intervention might work
Ergometrine is ergot in origin and was recovered first as a product
of a fungus, Claviceps purpurea, and used in obstetrics for the first
time in 1582. This use ended in 1822 due to uterine rupture, still-
birth andmaternal death from inaccurate doses and ergotism (gan-
grene and convulsive forms) (De Groot 1998; Van Dongen 1995).
However, ergot alkaloids were found to be more useful and less
harmful for obstetric practice in the form of ergometrine in 1932
byMoir and Dale (Dunn 2002). They have specific uterotonic ac-
tion through adrenergic receptors with less vasoconstrictive ability,
and they prevent excessive bleeding after childbirth. Two chemi-
cal ergot alkaloids are ergonovine/ergometrine maleate (ergotrate)
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and methylergonovine/methylergometrine maleate (methergine).
They produce persistent uterine contractions in the inner zone of
themyometrium through calcium channel mechanisms and actin-
myosin interaction, leading to the shearing effect on placental sep-
aration and less blood loss or PPH, but they may increase the risk
of maternal side effects such as hypertension and other compli-
cations of vasoconstriction (Brucker 2001; De Groot 1998; Dua
1994; Gowri 2003; Sultatos 1997; Taylor 1985). In addition, the
risks of partial retention or trapping of the placenta (or both),
manual removal of placenta, or uterine inversion or cord avulsion
are still concerns with ergometrine administration (Sorbe 1978).
Different types of ergot alkaloid, and different routes and timing
of administration, have been used for both prophylactic and ther-
apeutic purposes (Andersen 1998; Borri 1986; De Groot 1996b;
Moir 1979; Van Selm 1995). The most common ergot alkaloids
for obstetric treatment are ergometrine and methylergometrine.
Both injectable, ergometrine and methylergometrine are very un-
stablewhen stored unrefrigerated, anddeterioratewith higher stor-
age temperatures and exposure to light; therefore, they need to be
stored in a dark place at a temperature of 4 ºCelsius to 8 ºCelsius.
Their oral forms also deteriorate within weeks or immediately af-
ter being taken from a sealed package or container or when stored
in increased temperatures and high humidity. Intravenous methy-
lergometrine administration induces both increased frequency of
uterine contractions and basal tone, with a decrease of amplitude
lasting at least 30 minutes and maintained for 60 to 90 minutes.
The uterine effect following oral administration is detected in 20
to 30 minutes, peaks at 60 to 70 minutes and is maintained for
120 minutes, but its effect is unpredictable (De Groot 1996a; De
Groot 1996b). Injectable oxytocin is much more stable than er-
gometrine and methylergometrine (De Groot 1996a; De Groot
1998; Hogerzeil 1996). Although the chemical instability and the
side effects of ergot alkaloids are of concern, clinical trials on the
use of ergot alkaloids in the third stage of labour for prevention
of PPH have been conducted (Andersen 1998; De Groot 1996b;
Sorbe 1978). Oral forms of ergot alkaloids might be useful for
women in some areas where intravenous or intramuscular admin-
istration is not possible. A systematic review on the effectiveness
and safety of ergot alkaloids in the third stage of labour is needed.
Why it is important to do this review
Systematic reviews on the comparison of ergot alkaloid versus oxy-
tocin, prostaglandins, syntometrine and carbetocin are published
in theCochrane Library (McDonald 2004; Su 2012; Tunçalp 2012;
Westhoff 2013). Nevertheless, there still is a gap in knowledge on
the effectiveness and safety of prophylactic use of ergot alkaloids
in the third stage of labour compared with no uterotonic drugs,
as well as of different routes or timings of administration for the
prevention of PPH. This is an update of the review which was first
published in 2007 (Liabsuetrakul 2007).
O B J E C T I V E S
To determine the effectiveness and safety of prophylactic use of er-
got alkaloids in the third stage of labour by any route (intravenous,
intramuscular, or oral) compared with no uterotonic agents, for
the prevention of postpartum haemorrhage.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised trials or cluster-randomised trials comparing pro-
phylactic ergot alkaloids by any route (intravenous (IV), intramus-
cular (IM), or oral) with no uterotonic agents in the third stage
of labour among women giving birth vaginally. We included trials
that were presented only as abstracts if there was sufficient detail
(published and unpublished) to confirm eligibility.
Types of participants
Pregnant women anticipating a vaginal delivery.
Types of interventions
Any ergot alkaloid given prophylactically, by whatever route or
timing of administration, compared with no uterotonic agents.
Due to pharmacokinetic differences between different routes and
timings of administration, we planned to evaluate separately oral
versus IV or IM ergot alkaloids and administration before versus
after placental delivery.
We reviewed the following three comparisons:
1. ergot alkaloids (any route of administration) versus no
uterotonic agents;
2. IV/IM ergot alkaloids versus no uterotonic agents;
3. oral ergot alkaloids versus no uterotonic agents.
As comparisons of ergot alkaloids with other uterotonic agents
have been assessed in other reviews, such studies were not eligible
for inclusion in this review.
Types of outcome measures
We selected the outcome measures based on factors relating to
the effectiveness and safety of ergot alkaloids in terms of clinical
relevance for both maternal and neonatal outcomes.
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Primary outcomes
1. Mean blood loss (mL).
2. Postpartum haemorrhage (PPH) (clinically estimated or
measured blood loss of 500 mL or more).
3. ’Severe’ PPH (clinically estimated or measured blood loss of
1000 mL or more).
4. Maternal haemoglobin concentration at 24 to 48 hours
postpartum.
Secondary outcomes
Maternal outcomes
1. Blood transfusion.
2. Use of therapeutic uterotonics.
3. Length of third stage of labour (minutes).
4. Retained placenta or manual removal of the placenta, or
both.
5. Vomiting.
6. Nausea.
7. Elevation of blood pressure (mmHg).
8. Pain after birth requiring analgesia (not prespecified).
9. Headache (not prespecified).
10. Eclamptic fit (not prespecified).
11. Postnatal haemoglobin (Hb) less than 10 g/dL (not
prespecified).
12. Uterine subinvolution at routine follow-up (not
prespecified).
13. Postpartum febrile morbidity (not prespecified).
Neonatal outcomes
1. Apgar score equal to or less than six at five minutes.
2. Jaundice.
3. Not breastfeeding at discharge.
4. Admission to neonatal intensive care unit.
Search methods for identification of studies
The following search methods section of this review is based on a
standard template used by Cochrane Pregnancy and Childbirth.
Electronic searches
For this update, we searched Cochrane Pregnancy and Child-
birth’s Trials Register by contacting their Information Specialist
(19 September 2017).
The Register is a database containing over 24,000 reports of con-
trolled trials in the field of pregnancy and childbirth. For full search
methods used to populate Pregnancy andChildbirth’s Trials Regis-
ter including the detailed search strategies for CENTRAL, MED-
LINE, Embase and CINAHL; the list of handsearched journals
and conference proceedings; and the list of journals reviewed via
the current awareness service, please follow this link to the edi-
torial information about the Cochrane Pregnancy and Childbirth
in theCochrane Library and select the ’Specialized Register’ section
from the options on the left side of the screen.
Briefly, Cochrane Pregnancy and Childbirth’s Trials Register is
maintained by their Information Specialist and contains trials
identified from:
1. monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE (Ovid);
3. weekly searches of Embase (Ovid);
4. monthly searches of CINAHL (EBSCO);
5. handsearches of 30 journals and the proceedings of major
conferences;
6. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Search results are screened by two people and the full text of all
relevant trial reports identified through the searching activities de-
scribed above is reviewed. Based on the intervention described,
each trial report is assigned a number that corresponds to a spe-
cific Pregnancy and Childbirth review topic (or topics), and is
then added to the Register. The Information Specialist searches the
Register for each review using this topic number rather than key-
words. This results in a more specific search set that has been fully
accounted for in the relevant review sections (Included studies;
Excluded studies).
In addition, we searched ClinicalTrials.gov and the WHO Inter-
national Clinical Trials Registry Platform (ICTRP) for unpub-
lished, planned and ongoing trial reports (19 September 2017)
(See Appendix 1 for search terms used).
Searching other resources
We searched the reference lists of retrieved studies. We did not
apply any language or date restrictions.
Data collection and analysis
For methods used in the previous version of this review, see
Liabsuetrakul 2007.
For this update, the following methods were used for assessing the
reports that were identified as a result of the updated search. The
following methods section of this review is based on a standard
template used by Cochrane Pregnancy and Childbirth.
Selection of studies
In previous versions of the review and this updated version, the
contact author (Tippawan Liabsuetrakul (TL)) assessed all poten-
tial studies identified as a result of the search strategy, using title
and abstract, and searched for the full texts. Two review authors
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(TL andKrantarat Peeyananjarassri (KP)) independently reviewed
the full texts regarding types of studies, participants, interventions
and outcomes, based on the prespecified inclusion criteria and us-
ing a trial eligibility form. We resolved any disagreement through
discussion or, if required, we consulted the third review author
(Thanapan Choobun (TC)).
Data extraction and management
Two review authors (TL and TC)) independently assessed the va-
lidity of each included study using the criteria outlined in the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011). There was no attempt to mask the authors’ names, insti-
tutions, source of the publication or results when applying the
inclusion criteria.
We designed a form to extract data. For eligible studies, two review
authors (TL and KP) independently extracted the data using the
agreed form. We resolved discrepancies through discussion or, if
required, we consulted the third review author. Data were entered
into Review Manager software (RevMan 2014), and checked for
accuracy.
When information regarding any of the above was unclear, we
planned to contact authors of the original reports to provide fur-
ther details.
Assessment of risk of bias in included studies
Two review authors (TL and KP) independently assessed risk of
bias for each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
Any disagreement was resolved by discussion or by involving a
third assessor.
1) Random sequence generation (checking for possible
selection bias)
We described for each included study the method used to generate
the allocation sequence in sufficient detail to allow an assessment
of whether it should produce comparable groups.
We assessed the method as:
• low risk of bias (any truly random process, e.g. random
number table; computer random number generator);
• high risk of bias (any non-random process, e.g. odd or even
date of birth; hospital or clinic record number);
• unclear risk of bias.
2) Allocation concealment (checking for possible selection
bias)
We described for each included study the method used to con-
ceal allocation to interventions prior to assignment and assessed
whether intervention allocation could have been foreseen in ad-
vance of, or during recruitment, or changed after assignment.
We assessed the methods as:
• low risk of bias (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth);
• unclear risk of bias.
3.1) Blinding of participants and personnel (checking for
possible performance bias)
We described for each included study the methods used, if any, to
blind study participants and personnel from knowledge of which
intervention a participant received. We considered that studies
were at low risk of bias if they were blinded, or if we judged that
the lack of blinding unlikely to affect results. We assessed blinding
separately for different outcomes or classes of outcomes.
We assessed the methods as:
• low, high or unclear risk of bias for participants;
• low, high or unclear risk of bias for personnel.
3.2) Blinding of outcome assessment (checking for possible
detection bias)
We described for each included study the methods used, if any, to
blind outcome assessors from knowledge of which intervention a
participant received. We assessed blinding separately for different
outcomes or classes of outcomes.
We assessed methods used to blind outcome assessment as:
• low, high or unclear risk of bias.
4) Incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data)
We described for each included study, and for each outcome or
class of outcomes, the completeness of data including attrition and
exclusions from the analysis. We stated whether attrition and ex-
clusions were reported and the numbers included in the analysis at
each stage (compared with the total randomised participants), rea-
sons for attrition or exclusion where reported, and whether miss-
ing data were balanced across groups or were related to outcomes.
Where sufficient information was reported, or could be supplied
by the trial authors, we planned to re-include missing data in the
analyses which we undertook.
We assessed methods as:
• low risk of bias (e.g. no missing outcome data; missing
outcome data balanced across groups);
• high risk of bias (e.g. numbers or reasons for missing data
imbalanced across groups; ‘as treated’ analysis done with
substantial departure of intervention received from that assigned
at randomisation);
• unclear risk of bias.
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5) Selective reporting (checking for reporting bias)
We described for each included study how we investigated the
possibility of selective outcome reporting bias and what we found.
We assessed the methods as:
• low risk of bias (where it is clear that all of the study’s
prespecified outcomes and all expected outcomes of interest to
the review have been reported);
• high risk of bias (where not all the study’s prespecified
outcomes have been reported; one or more reported primary
outcomes were not prespecified; outcomes of interest are
reported incompletely and so cannot be used; study fails to
include results of a key outcome that would have been expected
to have been reported);
• unclear risk of bias.
6) Other bias (checking for bias due to problems not
covered by 1) to 5) above)
We described for each included study any important concerns we
had about other possible sources of bias.
7) Overall risk of bias
We made explicit judgements about whether studies were at high
risk of bias, according to the criteria given in the Handbook (
Higgins 2011). With reference to 1) to 6) above, we planned to
assess the likely magnitude and direction of the bias and whether
we considered it is likely to impact on the findings. In future
updates, we will explore the impact of the level of bias through
undertaking sensitivity analyses; see Sensitivity analysis.
Assessment of the quality of the evidence using the
GRADE approach
For this update, TL assessed the quality of the evidence using the
GRADE approach as outlined in the GRADE handbook. These
assessments were checked by a second person (a Researcher from
Cochrane Pregnancy and Childbirth). We assessed the quality of
the body of evidence relating to the following outcomes for the
main comparison.
1. Mean blood loss (mL).
2. PPH (clinically estimated or measured blood loss of 500
mL or more).
3. ’Severe’ PPH (clinically estimated or measured blood loss of
1000 mL or more).
4. Maternal haemoglobin concentration at 24 to 48 hours
postpartum (g/dL).
5. Use of therapeutic uterotonics.
6. Elevation of blood pressure.
7. Pain after birth requiring analgesia.
We used the GRADEpro Guideline Development Tool to import
data from Review Manager 5 (RevMan 2014), in order to create
’Summary of findings’ tables. A summary of the intervention effect
and a measure of quality for each of the above outcomes was
produced using the GRADE approach. The GRADE approach
uses five considerations (study limitations, consistency of effect,
imprecision, indirectness and publication bias) to assess the quality
of the body of evidence for each outcome. The evidence can be
downgraded from ’high quality’ by one level for serious (or by
two levels for very serious) limitations, depending on assessments
for risk of bias, indirectness of evidence, serious inconsistency,
imprecision of effect estimates or potential publication bias.
Measures of treatment effect
Dichotomous data
For dichotomous data, we presented results as summary risk ratio
with 95% confidence intervals.
Continuous data
We used the mean difference if outcomes were measured in the
same way between trials. In future updates, if appropriate, we
will use the standardised mean difference to combine trials that
measure the same outcome, but use different methods.
Unit of analysis issues
Cluster-randomised trials
None of the included studies were cluster-randomised trials.
In future updates, if identified and eligible, we will include clus-
ter-randomised trials in the analyses along with individually ran-
domised trials. We will adjust their sample sizes using the methods
described in the Handbook, using an estimate of the intracluster
correlation coefficient (ICC) derived from the trial (if possible),
from a similar trial or from a study of a similar population. If we
use ICCs from other sources, we will report this and conduct sen-
sitivity analyses to investigate the effect of variation in the ICC. If
we identify both cluster-randomised trials and individually-ran-
domised trials, we plan to synthesise the relevant information.
We will consider it reasonable to combine the results from both
if there is little heterogeneity between the study designs and the
interaction between the effect of intervention and the choice of
randomisation unit is considered to be unlikely.
We will also acknowledge heterogeneity in the randomisation unit
and perform a subgroup analysis to investigate the effects of the
randomisation unit.
Cross-over trials
Cross-over trials are not eligible for inclusion.
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Other unit of analysis issues
Five of the included studies had more than two treatment groups
(DeGroot 1996b; Howard 1964; Ilancheran 1990; Kerekes 1979;
McGinty 1956). For these studies we included only two of the
relevant groups that met the inclusion criteria in order to include
data into single pair-wise comparisons.
Dealing with missing data
For included studies, levels of attrition were noted. In future up-
dates, if more eligible studies are included, the impact of including
studies with high levels of missing data in the overall assessment
of treatment effect will be explored by using sensitivity analysis.
For all outcomes, we carried out analyses, as far as possible, on an
intention-to-treat basis (i.e. we attempted to include all partici-
pants randomised to each group in the analyses). The denominator
for each outcome in each trial was the number randomised minus
any participants whose outcomes were known to be missing.
Assessment of heterogeneity
We assessed statistical heterogeneity in each meta-analysis using
the Tau², I² and Chi² statistics. We regarded heterogeneity as sub-
stantial if I² was greater than 30% and either Tau² was greater than
zero, or there was a low P value (less than 0.10) in the Chi² test
for heterogeneity. If we identified substantial heterogeneity (above
30%), we planned to explore it by prespecified subgroup analysis.
Assessment of reporting biases
In future updates, if there are 10 or more studies in the meta-
analysis, we will investigate reporting biases (such as publication
bias) using funnel plots. We will assess funnel plot asymmetry
visually. If asymmetry is suggested by a visual assessment, we will
perform exploratory analyses to investigate it.
Data synthesis
We carried out statistical analysis using Review Manager software
(RevMan 2014). We used fixed-effect meta-analysis for combin-
ing data where it was reasonable to assume that studies were esti-
mating the same underlying treatment effect, i.e. where trials were
examining the same intervention, and the trials’ populations and
methods were judged sufficiently similar.
If there was clinical heterogeneity sufficient to expect that the un-
derlying treatment effects differed between trials, or if substan-
tial statistical heterogeneity was detected, we used random-effects
meta-analysis to produce an overall summary if an average treat-
ment effect across trials was considered clinically meaningful. The
random-effects summary was treated as the average range of possi-
ble treatment effects and wewill discuss the clinical implications of
treatment effects differing between trials. If the average treatment
effect is not clinically meaningful, we will not combine trials. If
we used random-effects analyses, the results were presented as the
average treatment effect with 95% confidence intervals, and the
estimates of Tau² and I².
Subgroup analysis and investigation of heterogeneity
If we identified substantial heterogeneity, we planned to investigate
it using subgroup analyses and sensitivity analyses and to consider
whether an overall summary was meaningful, and if so, to use
random-effects analysis to produce it.
We planned to carry out the following subgroup analyses.
1. Use of ergot alkaloids with or without active management
of third stage of labour.
2. Use of ergot alkaloids before or after placental delivery.
3. Use of ergot alkaloids in different doses.
There were too few studies included in any analyses with details
on prespecified subgroups to make subgroup analysis possible.
If there are enough data in future updates of this review, we will
use the following outcomes in subgroup analyses.
1. Mean blood loss (mL).
2. PPH (clinically estimated or measured blood loss of 500
mL or more).
3. ’Severe’ PPH (clinically estimated or measured blood loss of
1000 mL or more).
4. Maternal haemoglobin concentration at 24 to 48 hours
postpartum (g/dL).
We will assess subgroup differences by interaction tests available
withinReviewManager (RevMan 2014).Wewill report the results
of subgroup analyses quoting the Chi² statistic and P value, and
the interaction test I² value.
Sensitivity analysis
We carried out sensitivity analyses to explore the effect of risk of
bias assessed by concealment of allocation, high attrition rates, or
both, with studies being at high risk of bias excluded from the
analyses in order to assess whether this makes any difference to the
overall result. We performed a sensitivity analysis for all the out-
comes which showed substantial heterogeneity by excluding trials
which we classified as at high risk of bias in the main comparison.
R E S U L T S
Description of studies
Results of the search
See Figure 1.
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Figure 1. Study flow diagram.
An updated search on 19 September 2017 retrieved 42 trial re-
ports. After screening, we excluded 30 reports and assessed 12
new reports of 11 studies. We excluded all 11 studies. For 10 of
these studies, the interventionwas not that of this review (Adhikari
2007; Boopathi 2014; Dhananjaya 2014; Ezeama 2014; Fawzy
2012; Gupta 2014; Is 2012; Patil 2013; Sharma 2014; Shrestha
2008). The remaining study, identified from the clinical trials reg-
istry search, did not provide details of a contact person and so it
was not possible to obtain any further information relating to the
results (EudraCT2010-01980-42).
We also reassessed and included two studies that were previously
excluded due to not reporting outcomes of interest (Ilancheran
1990; Jolivet 1978). This updated review now includes eight ran-
domised controlled trials.
Included studies
A total of 4009 women participated in the eight included stud-
ies comparing any ergot alkaloids with placebo or no treatment
(Begley 1990; Daley 1951; De Groot 1996b; Howard 1964;
Ilancheran 1990; Jolivet 1978; Kerekes 1979; McGinty 1956).
1) Study location and settings
All studies were conducted in high-income countries with low
maternal mortality ratios, namely England, Hungary, Ireland, the
Netherlands, the United States, France and Singapore.
2) Participants
All participants included in these studies were delivered vaginally.
The criteria for inclusion and exclusion were clearly defined in
three studies (Begley 1990; Daley 1951; De Groot 1996b). One
study identified participants as women who had a spontaneous
vaginal delivery without complications; definitions of complica-
tions were not given (Kerekes 1979). The remaining four studies
included women who delivered vaginally; the exclusion criteria
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were not provided in the report (Howard 1964; McGinty 1956;
Ilancheran 1990; Jolivet 1978). Women with hypertension or car-
diovascular diseases were excluded from participating in two stud-
ies (Begley 1990; De Groot 1996b).
3) Interventions
The studies compared ergot alkaloids with no treatment (Begley
1990; Daley 1951; Ilancheran 1990; Jolivet 1978; Kerekes 1979),
or a placebo (De Groot 1996b; Howard 1964; McGinty 1956).
Three studies randomised participants into three comparison
groups (De Groot 1996b; Howard 1964; Kerekes 1979), and
two studies randomised into four comparison groups (Ilancheran
1990; McGinty 1956). Ergot alkaloids used were either er-
gometrine/ergonovine or methylergometrine/methylergonovine/
methylergobasine. There were various routes of administration:
intravenous infive studies (Begley 1990;Howard 1964; Ilancheran
1990; Kerekes 1979; McGinty 1956), intramuscular in two stud-
ies (Daley 1951; Jolivet 1978), and oral in one study (De Groot
1996b). Doses of intravenous or intramuscular ergometrine or
methylergometrine varied from 0.2 mg (Howard 1964; Jolivet
1978; Kerekes 1979; McGinty 1956), to 0.5 mg (Begley 1990;
Daley 1951), and no clearly defined dose (Ilancheran 1990); and
the dose of oral ergometrine was 0.4 mg (De Groot 1996b).
Most studies administered ergot alkaloids in the third stage of
labour (Begley 1990; Daley 1951; De Groot 1996b; Howard
1964; Ilancheran 1990; Jolivet 1978; Kerekes 1979; McGinty
1956); in one study administration occurred after placental de-
livery (Howard 1964). There were three studies which described
the method of placental delivery: one by active management of
third stage of labour (Begley 1990); two by physiological placental
separation (Daley 1951; De Groot 1996b). The remaining studies
gave no details of the method of placental delivery (Howard 1964;
Ilancheran 1990; Jolivet 1978; Kerekes 1979; McGinty 1956).
There were five studies with three or more arms comparing er-
got alkaloids with placebo or other uterotonic drugs (De Groot
1996b; Howard 1964; Ilancheran 1990; Kerekes 1979; McGinty
1956).
4) Outcomes
The largest study reported all prespecified outcome measures
(Begley 1990). The following maternal outcomes not prespeci-
fied in the review are reported: postnatal haemoglobin (Hb) less
than 10 g/dL (Begley 1990); headache (Begley 1990; McGinty
1956); pain after birth requiring analgesia (Begley 1990); eclamp-
tic fit (Begley 1990; McGinty 1956); uterine subinvolution at
routine follow-up (Kerekes 1979); postpartum febrile morbidity
(Kerekes 1979); prostaglandin levels (Ilancheran 1990); and new-
born birthweight and quantity of milk in 24 hours (Jolivet 1978).
We did not analyse the outcome of prostaglandins, newborn birth-
weight and quantity of milk in this review. Blood loss was ob-
served in six studies: clinically estimated in three (Begley 1990;
Daley 1951;Howard 1964),measured by gravimetric method (De
Groot 1996b), collection of blood in a container (Kerekes 1979),
and non-specified method (Ilancheran 1990). Maternal Hb con-
centration was checked at 48 to 72 hours postpartum in two trials
(Begley 1990; Kerekes 1979). However, mean blood loss and ma-
ternal Hb concentration data could not be extracted in one study
because the authors did not report the number in the result and
noted only a significant difference between the comparison groups
(Kerekes 1979). Two studies reported manual removal of the pla-
centa (Begley 1990; De Groot 1996b), and one study reported
retained placenta for 60 minutes or more (Daley 1951). The in-
cidence of blood transfusion was noted in three studies (Begley
1990; De Groot 1996b; McGinty 1956). The use of therapeutic
uterotonics was described in three studies (Begley 1990; De Groot
1996b; Howard 1964). The duration of the third stage of labour
was described as the mean length of the third stage (Begley 1990;
Daley 1951; De Groot 1996b; Kerekes 1979), and not as third
stage of labour lasting more than 30 minutes, which was a pre-
specified outcome of this review; one of the studies did not present
the standard deviations (De Groot 1996b), so we only analysed
three studies for this outcome. The elevation of blood pressure was
measured in three studies (Begley 1990; Howard 1964; McGinty
1956), but the definitions varied: diastolic blood pressure greater
than 95 mmHg (Begley 1990), the increase of systolic or dias-
tolic blood pressure greater than 10 mmHg (Howard 1964), or
the increase of systolic blood pressure 20 mmHg or more or sys-
tolic blood pressure greater than 170 mmHg (McGinty 1956).
Vomiting and nausea were reported in two studies (Begley 1990;
McGinty 1956). None of the neonatal outcomes were reported in
the included studies.
5) Dates of study, funding sources and declarations of
interest
Dates when the studies were conducted were reported as: 1 Oc-
tober 1987 to 31 October 1988 (Begley 1990); July 1993 to July
1994 (De Groot 1996b); and August 1962 to July 1963 (Howard
1964). In one study, it was reported that “The experiment was
started in the spring of 1949”, but the completion date was not re-
ported (Daley 1951). Study dates were not reported in four studies
(Ilancheran 1990; Jolivet 1978; Kerekes 1979; McGinty 1956
Sources of funding included: the Research andDevelopmentTrust
of the Coombe Hospital in one study (Begley 1990), and a Public
Health Service Grant No. GM-08943-02 and No. AO-00555-03
in another one study (Howard 1964). Funding sources were not
reported in the remaining studies (Daley 1951; De Groot 1996b;
Ilancheran 1990; Jolivet 1978; Kerekes 1979; McGinty 1956).
There was no information in any of the studies on declarations of
interest among primary researchers.
Please see the table Characteristics of included studies for further
details.
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Excluded studies
The details of all excluded studies are in the table Characteristics
of excluded studies.
In the previous version of the review (Liabsuetrakul 2007), we
excluded 29 studies by screening using title, abstract or studies
within the scope of other Cochrane Reviews. These include nine
studies where the comparison was with prostaglandin (Amant
1999; Baumgarten 1983; Caliskan 2002; Chatterjee 2000; Diab
1999; Lam 2004; Penaranda 2002; Rajwani 2000; Vimala 2004);
11 studies where oxytocin was the comparator (Barbaro 1961;
Bonham 1963; Docherty 1981; Francis 1965a; Francis 1965b;
Fugo 1958; Huh 2004; Kikutani 2003; Soiva 1964; Stearn 1963;
Symes 1984); seven studies where syntometrine was the com-
parator (Khan 1995; Lamont 2001; Mitchell 1993; Nieminen
1963; Vaughan 1974; Yardim 1967; Yuen 1995); one study of nip-
ple stimulation (Badhwar 1991); and one study of syntometrine
(OCM 505) (Carpén 1968). We then evaluated the full texts of
the remaining 32 studies, and excluded 26 of these: 18 because
the studied intervention was not that of this review (Chukudebelu
1963; Forster 1957; Groeber 1960; Jago 2007; Kemp 1963; Moir
1979; Moodie 1976; Moore 1956; Orji 2008; Paull 1977; Pei
1996; Ramesh 1983; Reddy 2001; Rooney 1985; Saito 2007;
Singh 2009; Thilaganathan 1993; Thornton 1988); three because
the studies were not randomised controlled trials (Friedman 1957;
Hacker 1979; Sorbe 1978); one because it did not include women
having a vaginal delivery (Dweck 2000); and four because there
were no outcomes of interest (Ilancheran 1990; Jolivet 1978; Terry
1970;Weiss 1975). However, in this current update, we reassessed
four studies to make sure the reasons for exclusion were still valid
and could not introduce outcome reporting bias (Ilancheran 1990;
Jolivet 1978; Terry 1970; Weiss 1975). Two studies were still ex-
cluded (Terry 1970; Weiss 1975): we excluded one because the
comparison was with syntometrine (Terry 1970), and one because
it did not measure any outcomes from this review (Weiss 1975).
We included the remaining two studies (Ilancheran 1990; Jolivet
1978), but one did not contribute any data to the review (Jolivet
1978).
We excluded the 11 studies from the 2017 search. The inter-
vention used in 10 studies was not that of this review (Adhikari
2007; Boopathi 2014; Dhananjaya 2014; Ezeama 2014; Fawzy
2012; Gupta 2014; Is 2012; Patil 2013; Sharma 2014; Shrestha
2008), and one study identified from the clinical trials registry
search did not provide details of a contact person and so it was not
possible to obtain any further information relating to the results
(EudraCT2010-01980-42).
Risk of bias in included studies
According to the ’Risk of bias’ tool, three studies had a low risk
of bias (Begley 1990; De Groot 1996b; Howard 1964), and five
studies showed a high risk of bias (Daley 1951; Ilancheran 1990;
Jolivet 1978; Kerekes 1979; McGinty 1956) (Figure 2; Figure 3).
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
We considered two studies to have adequate sequence generation
and allocation concealment (Begley 1990; De Groot 1996b). Se-
quence generation and allocation concealment were inadequate in
one study due to the use of alternation by weekends when teams of
obstetricians and midwives changed (Daley 1951). We were un-
able to make a judgement about whether sequence generation and
allocation concealment was adequate or inadequate in five studies
due to there being no details of the methods used (Howard 1964;
Ilancheran 1990; Jolivet 1978; Kerekes 1979; McGinty 1956).
We did not request additional information regarding allocation
concealment from the trial authors of these studies because they
were published before 1980.
Blinding
We assessed that the method of blinding (participants and care-
giver) was of low risk of bias in two studies that compared er-
gometrine/methylergometrine with placebo (De Groot 1996b;
Howard 1964). One study mentioned that normal saline was
used as the control; however, the appearance of methergine or
ergonovine was not described (i.e. whether it was identical with
control) thus we judged its blinding as unclear (McGinty 1956).
Due to the comparison being no treatment or different route of
drug administration in the remaining studies (Begley 1990; Daley
1951; Ilancheran 1990; Jolivet 1978; Kerekes 1979), we consid-
ered that it was not possible to blind and so deemed these studies
to be at high risk of performance bias.
In two studies we judged that it was possible for blinding of out-
come assessment to be performed (De Groot 1996b; Howard
1964); we judged that it was unlikely that blinding of outcome
assessment was possible in five studies (Begley 1990; Daley 1951;
Ilancheran 1990; Jolivet 1978; Kerekes 1979); and we judged that
it was not clear whether it was possible to perform blinding of
outcome assessment in one study (McGinty 1956).
Incomplete outcome data
We assessed that all participants who entered the study were ac-
counted for in the outcome measures and analyses in five tri-
als (Begley 1990; Daley 1951; De Groot 1996b; Kerekes 1979;
McGinty 1956). In Howard 1964, not all participants who en-
tered the study were accounted for in the outcome measures and
analyses, but the loss of participants at follow-up was less than
10%. In two studies, a number of participants in the outcomes
identified were not reported (Ilancheran 1990; Jolivet 1978), and
so we deemed these studies to have high risk of bias for this do-
main.
Selective reporting
We assessed that in seven included trials published all expected
prespecified outcomes in the reports. One study reported one ad-
ditional outcome in the results which was not defined in themeth-
ods, thus we rated as high risk of reporting bias (Ilancheran 1990).
Other potential sources of bias
We did not identify other important potential source of bias.
Effects of interventions
See: Summary of findings for the main comparison Ergot
alkaloids (any route of administration) versus no uterotonic
agents in the third stage of labour; Summary of findings 2
Intravenous/intramuscular ergot alkaloids versus no uterotonic
agents in the third stage of labour; Summary of findings 3 Oral
ergot alkaloids versus no uterotonic agents in the third stage of
labour
We included eight studies with a total of 4009 women: 2031
women in the ergot alkaloids group and 1978 in the placebo or
no treatment group. We analysed data from seven studies com-
paring ergot alkaloids with no uterotonic agents, with a total of
2001 women in the ergot alkaloids group and 1950 women in
the placebo or no treatment group. Effects of interventions are
presented in three comparisons: any route of administration, in-
travenous/intramuscular administration, or oral regimens, versus
no uterotonic agents (seven, six and one included studies, respec-
tively).We performed a sensitivity analysis for the outcomes which
showed substantial heterogeneity by excluding trialswhichwe clas-
sified as having high risk of bias. Where significant heterogeneity
was observed, we analysed results using a random-effects model.
1) Ergot alkaloids (any route of administration)
versus no uterotonic agents
Primary outcomes
For four primary outcomes, five included studies compared any
route of ergot alkaloids with no treatment, of which four stud-
ies used the intravenous/intramuscular route of administration
(Begley 1990; Daley 1951; Howard 1964; Ilancheran 1990), and
one study used the oral route (De Groot 1996b). The use of er-
got alkaloids decreased mean blood loss (mean difference (MD) -
80.52 mL, 95% confidence interval (CI) -96.39 to -64.65 mL; 3
studies, 2718 women; moderate-quality evidence; Analysis 1.1).
Postpartum haemorrhage (PPH), blood loss of at least 500 mL,
was also reduced with ergot alkaloids (average risk ratio (RR) 0.52,
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95% CI 0.28 to 0.94; random-effects, Tau² = 0.32, I² = 83%;
123/1851 versus 220/1857 women; 5 studies, 3708 women, low-
quality evidence; Analysis 1.2). There were no clear differences in
blood loss of at least 1000 mL between the ergot alkaloids and no
treatment groups (average RR 0.32, 95% CI 0.04 to 2.59; ran-
dom-effects, Tau² = 1.74, I² = 74%; 13/851 versus 27/867women;
1 study, 1429 women; very low-quality evidence; Analysis 1.3).
There was an increase in mean maternal haemoglobin concentra-
tion at 48 to 72 hours of postpartum in the ergot alkaloids group,
but data were only reported in one study (MD 0.50 g/dL, 95%
CI 0.38 to 0.62; 1 study, 1429 women; Analysis 1.4).
Secondary outcomes
No difference was demonstrated in the incidence of blood transfu-
sion when ergot alkaloid was compared with no uterotonic agents
(RR 0.33, 95% CI 0.08 to 1.40; 2/951 versus 6/917 women; 3
studies, 1868 women; Analysis 1.5), but use of ergot alkaloid did
reduce the use of therapeutic uterotonics (average RR 0.37, 95%
CI 0.15 to 0.90; random-effects, Tau² = 0.56, I² = 89%; 60/1356
versus 177/1342 women; 3 studies, 2698 women; low-quality evi-
dence, Analysis 1.6). Compared with no treatment, ergot alkaloids
reduced the mean length of the third stage of labour by nearly two
minutes (MD -1.70 minutes, 95% CI -3.33 to -0.06; random-
effects, Tau² = 3.68, I² = 94%; 3 studies, 2522 women, Analysis
1.7), but there were no differences between groups in the risk of
retained placenta or manual removal of the placenta (average RR
3.86, 95% CI 0.36 to 41.78; random-effects, Tau² = 3.43, I² =
81%; 38/1341 versus 20/1377 women; 3 studies, 2718 women;
Analysis 1.8).
For the remaining maternal secondary outcomes, only the intra-
venous or intramuscular route of administration was used (three
studies: Begley 1990; Howard 1964; McGinty 1956); therefore,
the results were similar to the findings of comparisons of intramus-
cular or intramuscular ergot alkaloids compared with no utero-
tonic agents, reported below in comparison two. We could not
find the studies reporting neonatal secondary outcomes.
The number of included studies was too few to conduct subgroup
analyses based on the use of ergot alkaloids with or without active
management of third stage of labour, before or after placental
delivery, and in different doses.
None of the studies reported on any of our prespecified neonatal
outcomes: Apgar score equal to or less than six at five minutes;
jaundice; not breastfeeding at discharge; and admission toneonatal
intensive care.
Sensitivity analyses
There were three studies at high risk of bias for either alloca-
tion concealment or attrition bias (Daley 1951; Ilancheran 1990;
Jolivet 1978). We excluded these studies for the following analy-
ses: mean blood loss (mL) (Analysis 1.1); estimated or measured
blood loss of at least 500 mL (Analysis 1.2); length of third stage
of labour (minutes) (Analysis 1.7); retained placenta or manual
removal of placenta, or both (Analysis 1.8). This made little dif-
ference to the overall results for mean blood loss (mL) (Analysis
4.1). After excluding two trials (Daley 1951; Ilancheran 1990),
for estimated or measured blood loss of at least 500 mL the confi-
dence intervals increased slightly to cross the line of no effect and
heterogeneity increased (average RR 0.44, 95% CI 0.16 to 1.24;
3 studies, 2698 women; I2 = 92%; Analysis 4.2). For length of
third stage of labour (minutes), excluding one study, Daley 1951,
again resulted in the confidence interval increasing slightly to cross
the line of no effect, but heterogeneity decreased from 66% to
42% (MD -1.07 minutes, 95% CI -2.32 to 0.19; 2 studies, 1522
women; I2 = 42%; Analysis 4.3). For the outcome retained pla-
centa or manual removal of placenta, removing one study, Daley
1951, from the analysis changed the direction of effect from no
difference to a reduction in retained placenta or manual removal
of placenta in favour of the control group and heterogeneity com-
pletely disappeared (RR 12.79, 95% CI 2.40 to 68.19; 2 studies,
1718 women; I2 = 0%; Analysis 4.4).
2) Intravenous or intramuscular ergot alkaloids
compared with no uterotonic agents
Primary outcomes
Four included studies compared the intravenous/intramuscular
route of administration of ergot alkaloids with no treatment
(Begley 1990; Daley 1951; Howard 1964; Ilancheran 1990). Two
studies comparing intravenous/intramuscular ergot alkaloids with
no treatment, found that the use of ergot alkaloids decreasedmean
blood loss (mean difference (MD) -81.75 mL, 95% confidence
interval (CI) -97.88 to -65.61 mL; 2 studies, 2429 women; mod-
erate-quality evidence; Analysis 2.1). When blood loss of at least
500 mL (moderate PPH) was considered, there was significant
heterogeneity, thus we analysed this outcome using a random-ef-
fects model and ergot alkaloids were associated with a lower mod-
erate PPH rate (average RR 0.41, 95% CI 0.22 to 0.75; random-
effects, Tau² = 0.22, I² = 67%; 69/1705 versus 165/1714 women;
4 studies, 3419 women; low-quality evidence; Analysis 2.2). One
study comparing ergot alkaloids with no treatment, reported a re-
duction in blood loss of at least 1000 mL (RR 0.09, 95% CI 0.01
to 0.72; 1 study, 1429 women; low-quality evidence; Analysis 2.3)
and increased mean maternal haemoglobin concentration at 48
to 72 hours postpartum (MD 0.50 g/dL, 95% CI 0.38 to 0.62;
1 study, 1429 women; moderate-quality evidence; Analysis 2.4)
with ergot alkaloids.
Secondary outcomes
Nodifference was demonstrated in the incidence of blood transfu-
sion when ergot alkaloid was compared with no uterotonic agents
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(RR 0.34, 95% CI 0.05 to 2.16; 1/805 versus 3/774 women; 2
studies, 1579 women; Analysis 2.5), but use of an ergot alkaloid
did reduce the use of therapeutic uterotonics (average RR 0.25,
95% CI 0.10 to 0.66; random-effects, Tau² = 0.41, I² = 86%; 39/
1210 versus 151/1199 women; 2 studies, 2409 women; low-qual-
ity evidence; Analysis 2.6). Mean length of third stage of labour
was significantly less in the ergot alkaloid group (MD -1.70 min-
utes, 95% CI -3.33 to -0.06; Tau² = 1.36, I² = 66%; 3 studies,
2522 women; Analysis 2.7) using random-effects analysis.
The risk of retained placenta or manual removal of the placenta,
or both, was not demonstrated (average RR 3.75, 95% CI 0.14
to 99.71; random-effects, Tau² = 5.06, I² = 90%; 36/1195 versus
20/1234 women; 2 studies, 2429 women; Analysis 2.8). It should
be noted that the outcomes of these two studies had opposite
directions of effect. In one study (Begley 1990), the risk of manual
removal of placenta was increased in the ergot alkaloid group (RR
19.51, 95% CI 2.62 to 145.36), but in the other study (Daley
1951), the risk of retained placenta at 60 minutes or more was not
increased.
In two studies, vomiting and nausea were increased with ergot al-
kaloids (vomiting: average RR 6.82, 95% CI 0.37 to 126.26; ran-
dom-effects, Tau² = 2.10, I² = 47%; 13/805 versus 0/774 women;
2 studies, 1579 women; Analysis 2.9; nausea: average RR 8.63,
95% CI 0.26 to 284.55; random-effects, Tau² = 4.04, I² = 63%;
21/805 versus 0/774 women; 2 studies, 1579 women; Analysis
2.10). The following maternal adverse effects were increased with
intravenous or intramuscular ergot alkaloids compared with no
treatment: elevation of blood pressure (average RR 2.60, 95% CI
1.03 to 6.57; random-effects; Tau² = 0.55, I² = 84%; 299/1310
versus 166/1249 women; 3 studies, 2559 women; low-quality evi-
dence; Analysis 2.11); and pain after birth requiring analgesia (RR
2.53, 95% CI 1.34 to 4.78; 1 study, 1429 women; moderate-
quality evidence; Analysis 2.12). Significant heterogeneity for the
outcome elevation of blood pressure might be because different
definitions of elevated blood pressure were used.
None of the studies reported on any of our prespecified neonatal
outcomes: Apgar score equal to or less than six at five minutes;
jaundice; not breastfeeding at discharge; and admission toneonatal
intensive care.
Outcomes not prespecified
There was no evidence of a difference in the incidence of headache
(Analysis 2.13) and eclamptic fits (Analysis 2.14). One study re-
ported no difference of uterine subinvolution at routine follow-up
(Analysis 2.15), and postpartum febrile morbidity (Analysis 2.16).
One study reported a significant reduction of postnatal haemo-
globin less than 10 g/dL (RR 0.30, 95% CI 0.14 to 0.67; 1 study,
1429 women; Analysis 2.17).
3) Oral ergot alkaloids compared with no uterotonic
agents
One study, De Groot 1996b, compared oral ergometrine with
placebo and showed no significant benefit of ergometrine over
placebo in terms of mean blood loss (Analysis 3.1); blood loss
of at least 500 mL (Analysis 3.2) and 1000 mL (Analysis 3.3);
need for blood transfusion (Analysis 3.4); use of further oxytocics
(Analysis 3.5); and manual removal of the placenta (Analysis 3.6).
Data presented for length of third stage of labour could not be
extracted. Nomaternal adverse effects were reported. None of our
prespecified neonatal outcomes were reported: Apgar score equal
to or less than six at five minutes; jaundice; not breastfeeding at
discharge; and admission to neonatal intensive care.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Intravenous/ intramuscular ergot alkaloids versus no uterotonic agents in the third stage of labour
Patient or population: women in the third stage of labour
Settings: hospital sett ings in USA and Ireland
Intervention: intravenous/ intramuscular ergot alkaloids
Comparison: no uterotonic agents
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Intravenous/ intra-
muscular ergot alka-
loids versus no utero-
tonic agents
Mean blood loss (mL)
visual est imation
The mean blood loss
ranged across control
groups f rom 234.8 to
325.9 mL
The mean blood loss in
the intervent ion groups
was
81.75 mL lower
(97.88 to 65.61 lower)
2429
(2 studies)
⊕⊕⊕©
moderate1
Estimated or measured
blood loss of at least
500 mL
visual est imation
Study population RR 0.41
(0.22 to 0.75)
3419
(4 studies)
⊕⊕©©
low1,2
96 per 1000 39 per 1000
(21 to 72)
Medium risk population
83 per 1000 34 per 1000
(18 to 62)
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Estimated or measured
blood loss of at least
1000 mL
visual est imation
Study population RR 0.09
(0.01 to 0.72)
1429
(1 study)
⊕⊕©©
low 1,3
15 per 1000 1 per 1000
(0 to 11)
Medium risk population
15 per 1000 1 per 1000
(0 to 11)
Maternal haemoglobin
concentration at 24 to
48 hours postpartum
(g/dL)
The mean maternal
haemoglobin concen-
trat ion at 24 to 48 hours
postpartum in the con-
trol group was 12.09 g/
dL
The mean maternal
haemoglobin concen-
trat ion at 24 to 48 hours
postpartum in the inter-
vent ion groups was
0.5 g/dL higher
(0.38 to 0.62 higher)
1429
(1 study)
⊕⊕⊕©
moderate1
Use of therapeutic
uterotonics
Study population RR 0.25
(0.1 to 0.66)
2409
(2 studies)
⊕⊕©©
low1,2
126 per 1000 32 per 1000
(13 to 83)
Medium risk population
125 per 1000 31 per 1000
(13 to 83)
Elevation of blood
pressure
Study population RR 2.6
(1.03 to 6.57)
2559
(3 studies)
⊕⊕©©
low1,2
133 per 1000 346 per 1000
(137 to 874)
Medium risk population
120 per 1000 312 per 1000
(124 to 788)21
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Pain after birth requir-
ing analgesia (not pre-
specified)
Study population RR 2.53
(1.34 to 4.78)
1429
(1 study)
⊕⊕⊕©
moderate1
18 per 1000 46 per 1000
(24 to 86)
Medium risk population
18 per 1000 46 per 1000
(24 to 86)
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval; RR: Risk rat io; PPH: postpartum haemorrhage;mL: m illi l it re; g/dL: grams per decilit re
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Lim itat ions in study design (-1)
2 Inconsistency of results, high I2 value (-1)
3 Single study with few events (-1)
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Oral ergot alkaloids versus no uterotonic agents in the third stage of labour
Patient or population: women in the third stage of labour
Settings: a single study, hospital sett ing in the Netherlands
Intervention: oral ergot alkaloids
Comparison: no uterotonic agents
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Oral ergot alkaloids
versus no uterotonic
agents
Mean blood loss (mL)
visual est imation
The mean blood loss in
the control group was
520 mL
The mean blood loss in
the intervent ion groups
was
44 mL lower
(132.08 lower to 44.08
higher)
289
(1 study)
⊕⊕©©
low1
Estimated or measured
blood loss of at least
500 mL
visual est imation
Study population RR 0.96
(0.72 to 1.29)
289
(1 study)
⊕⊕©©
low1
385 per 1000 370 per 1000
(277 to 497)
Medium risk population
385 per 1000 370 per 1000
(277 to 497)
Estimated or measured
blood loss of at least
1000 mL
visual est imation
Study population RR 0.73
(0.36 to 1.5)
289
(1 study)
⊕⊕©©
low1
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112 per 1000 82 per 1000
(40 to 168)
Medium risk population
112 per 1000 82 per 1000
(40 to 168)
Maternal haemoglobin
concentration at 24 to
48 hours postpartum
(g/dL)
Not est imable Not est imable Not reported in the trial
Use of therapeutic
uterotonics
Study population RR 0.79
(0.47 to 1.34)
289
(1 study)
⊕⊕©©
low1
182 per 1000 144 per 1000
(86 to 244)
Medium risk population
182 per 1000 144 per 1000
(86 to 244)
Elevation of blood
pressure
Not est imable Not est imable Not reported in the trial
Pain after birth requir-
ing analgesia (not pre-
specified)
Not est imable Not est imable Not reported in the trial
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval; RR: Risk rat io; PPH: postpartum haemorrhage;mL: m illi l it re; g/dL: grams per decilit re
2
4
P
ro
p
h
y
la
c
tic
u
se
o
f
e
rg
o
t
a
lk
a
lo
id
s
in
th
e
th
ird
sta
g
e
o
f
la
b
o
u
r
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
8
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Single study with small sample size and wide conf idence interval (-2)
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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D I S C U S S I O N
Summary of main results
There was moderate-quality evidence that the use of ergot alka-
loids probably reduces mean blood loss, probably slightly reduces
moderate postpartum haemorrhage (PPH) (low-quality evidence)
and the use of therapeutic uterotonics (low-quality evidence), and
probably increases postnatal haemoglobin (Hb) level. Neverthe-
less, there was very low-quality evidence that the intervention
probablymakes little difference to severe PPH. Furthermore, there
wasmoderate-quality evidence that the use of ergot alkaloids prob-
ably leads to an increase in the frequency of women requiring anal-
gesia after birth due to pain. There was also low-quality evidence
to suggest that ergot alkaloids may slightly increase elevation of
blood pressure. The use of intravenous/intramuscular ergot alka-
loids may make little or no difference in terms of other adverse
effects (vomiting, nausea, headache or eclamptic fit) and results
were inconsistent on the risks of retained or manual removal of
placenta.
Overall completeness and applicability of
evidence
Intravenous/intramuscular ergot alkaloids decreased mean blood
loss and reduced the incidence of postpartum blood loss of at least
500 mL, which is in accordance with the results of a Cochrane
Review assessing the effectiveness of active versus expectant man-
agement in the third stage of labour (Begley 2015). Postpartum
blood loss of 1000 mL or more and postnatal Hb concentration
less than 10 g/dL were decreased, and there was an increase in
mean postnatal Hb in the intravenous ergot alkaloids group, but
data were from one study only (Begley 1990). These effects can
result from strong uterine contractions after giving ergot alkaloids
(De Groot 1995; De Groot 1996a; De Groot 1998), leading to a
reduction in the need for therapeutic uterotonics, but no change
in the incidence of blood transfusion. The reduction in the need
for therapeutic uterotonics was also found in the Cochrane Re-
views of oxytocin versus no uterotonic agents (Westhoff 2013) and
active versus expectant management in the third stage of labour
(Begley 2015). Mean length of the third stage of labour in the
ergot alkaloid group in this review was minimally decreased (two
minutes); however, previous Cochrane Reviews on prophylactic
use of other uterotonics in the third stage of labour compared
with no uterotonic agents have not shown this benefit (Tunçalp
2012; Westhoff 2013). Two-minute reduction in the third stage
of labour seems unlikely to be clinically significant; however, it is
a very critical period in case of bleeding.
No difference was demonstrated for the risk of retained placenta or
manual removal of the placenta, or both; heterogeneity was high
(81%) and confidence intervals wide (three trials: Begley 1990;
Daley 1951; De Groot 1996b). This finding was in accordance
with the results of the Cochrane Reviews of uterotonic versus no
uterotonic agents (Tunçalp 2012;Westhoff 2013) and active versus
expectant management in the third stage of labour (Begley 2015).
Likewise, this lack of a difference was also found in a Cochrane
review comparing a combination of ergot alkaloid and oxytocin
versus oxytocin (McDonald 2004).
Significant adverse events for elevation of blood pressure and pain
after birth requiring analgesia result from the effects of ergot al-
kaloids caused by persistent uterine contraction and vasoconstric-
tion (De Groot 1998; Den Hertog 2001; Van Dongen 1995), in
accordance with the Cochrane Reviews (Begley 2015;McDonald
2004). Data from case reports reported severe adverse effects (cere-
bral ischaemia, vasospasmandhypertensive encephalopathy) (Dua
1994; Taylor 1985), indicating that the drug should be used with
caution. There was only one study, De Groot 1996b, comparing
oral ergometrine versus placebo, which showed no significant risk
or benefit of ergometrine. This may be explained by there being
only a small number of women in the study, and therefore insuf-
ficient power to detect any difference. Easy deterioration of oral
ergot alkaloids immediately after being taken from a sealed pack-
age or container, and from being exposed to increased temperature
and high humidity (De Groot 1998), or longer latency time and
less effect on uterinemotility when comparedwith the intravenous
route, can lead to unpredictable bioavailability (De Groot 1996a).
According to the magnitude of ergot alkaloid effect, 19 pregnant
womenwould need to be given ergot alkaloids to prevent one addi-
tional pregnant woman from experiencing moderate PPH (num-
ber needed to treat for an additional beneficial outcome (NNTB)
19, 95% confidence interval (CI) 14 to 30), with simultaneous
harm of pain after birth (number needed to treat for an additional
harmful outcome (NNTH) 36, 95% CI 22 to 108) and elevation
of blood pressure (NNTH 10, 95% CI 8 to 15). Thus, with the
possible elevation in blood pressure, ergot alkaloids should be used
with caution in those women with high blood pressure.
Quality of the evidence
We included eight randomised controlled trials in this review. Ac-
cording to the ’Risk of bias’ tool, three studies had a low risk of bias
(Begley 1990; De Groot 1996b; Howard 1964), and five studies
showed a high risk of bias (Daley 1951; Ilancheran 1990; Jolivet
1978; Kerekes 1979; McGinty 1956) (Figure 2; Figure 3).
For the main comparison, ergot alkaloids versus no uterotonic
agents, the quality of the evidence for the outcomes ranged from
very low to moderate (see Summary of findings for the main
comparison). The quality of the evidence for mean blood loss was
moderate; there were limitations in the study design, which gave
us reason to downgrade our assessment of the evidence. The qual-
ity of evidence for moderate PPH and severe PPH was low and
very low. We downgraded our quality assessments for PPH due to
there being limitations in study design, inconsistency in results,
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and imprecision. Only one study contributed to the evidence for
maternal haemoglobin level 24 to 48 hours postpartum, and pain
after birth requiring the need for analgesia. We assessed the quality
of evidence for these outcomes as moderate, due to limitations in
study design. We also noted limitations in study design and incon-
sistency among the studies contributing to the evidence for the use
of therapeutic uterotonics and elevation of blood pressure, so we
judged the quality of evidence as low. The quality of the evidence
for the comparison of intravenous/intramuscular ergot alkaloids
versus no uterotonic agents was similar to the main comparison
of administration by any route, but most of the studies (seven of
eight) used the intravenous/intramuscular route (see Summary of
findings 2). Only one small study (289 women) compared oral
ergometrine with placebo and it showed no benefit of ergometrine
over placebo. We judged the quality of this evidence to be low
for all outcomes; we downgraded our assessment because of im-
precision due to the evidence coming from a single study with a
small sample size and wide confidence intervals (see Summary of
findings 3).
Potential biases in the review process
The possibility of introducing bias was present at every stage of
the review process. In order to minimise bias, two review authors
independently assessed studies for eligibility, undertook data ex-
traction and carried out GRADE quality assessments. We under-
took a comprehensive search strategy in order to minimise the po-
tential for publication bias. We also reassessed previously excluded
studies to ensure they had not been excluded due to not reporting
outcomes of interest in order to avoid outcome reporting bias.
Agreements and disagreements with other
studies or reviews
To date, there are no other published systematic reviews compar-
ing ergot alkaloids to no uterotonics. Two Cochrane Reviews com-
pared oxytocin versus no uterotonics or any uterotonics including
ergot alkaloids (Westhoff 2013), or ergot alkaloids plus oxytocin
versus oxytocin (McDonald 2004).
The effects found in this review, of ergot alkaloids administered
in the third stage of labour on reduction of moderate PPH and
use of therapeutic uterotonics (when compared with no uteroton-
ics), were similar to the findings of the oxytocin review by West-
hoff and colleagues (Westhoff 2013). A lower mean blood loss
was noted in our review, but it was not identified in any study
included in Westhoff 2013. No difference in the rate of manual
removal of the placenta was noted in our review which is in ac-
cordance with the Cochrane Reviews on oxytocin, misoprostol,
or syntometrine versus no uterotonic agents or other uterotonics
(McDonald 2004; Tunçalp 2012; Westhoff 2013). The combi-
nation of 5 IU of oxytocin plus 0.5 mg of ergot alkaloids (syn-
tometrine) showed a greater reduction of the risk ofmoderate PPH
and therapeutic uterotonics compared with 10 IU of oxytocin, but
the risks of elevation of diastolic blood pressure, vomiting, nau-
sea and combined vomiting and nausea were reported (McDonald
2004). The adverse effects associated with syntometrine may be
due to higher doses of ergot alkaloids in the combination.
One recently published network meta-analysis (NMA), Gallos
2018, suggests that ergot alkaloids are also beneficial in terms
of preventing PPH, though they appeared to be most effective
when combined with oxytocin. The authors of this NMA con-
cluded that ’ergometrine plus oxytocin combination, carbetocin,
and misoprostol plus oxytocin combination were most effective
for preventing PPH ≥ 500 mL than the current standard oxy-
tocin. Ergometrine plus oxytocin combination was more effective
for preventing PPH ≥ 1000 mL than oxytocin.’
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Prophylactic intramuscular (IM) or intravenous (IV) injections
of ergot alkaloids may be effective in reducing blood loss and
postpartum haemorrhage (PPH) (estimated blood loss of at least
500 mL), and increasing maternal haemoglobin. They may also
decrease the use of therapeutic uterotonics, but adverse effects
may include elevated blood pressure and pain after birth requiring
analgesia. There were no differences between use of ergot alkaloids
and no uterotonics in terms of other adverse effects (vomiting,
nausea, headache or eclamptic fit). There is a lack of evidence
on the effects on severe PPH, retained or manual removal of the
placenta and on the oral route of administering ergot alkaloids.
Implications for research
When ergot alkaloids were compared with no uterotonic agents,
there was some evidence to suggest beneficial effects in terms of
reduced postpartum blood loss and reduced use of additional ther-
apeutic uterotonics, but higher risk of elevation of blood pressure.
However, the participants in these trials were not at increased risk
of PPH and so the possible benefits to this group of women have
not really been assessed. The optimal dosing of, and route of ad-
ministration for, ergot alkaloids is inconclusive and future trials
could address this. The adverse effects of ergot alkaloids also need
to be seriously considered. None of the studies on prophylactic
use of uterotonics included in this review addressed neonatal out-
comes or serious morbidity from PPH, thus there is the need in
future trials to measure neonatal outcomes, serious morbidity in
the mother and possible adverse effects of ergometrine on lacta-
tion.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Begley 1990
Methods Randomisation in batches of 100 and allocation by sealed envelopes. No blinding
Participants Eligibility: women attending the antenatal clinic at Coombe hospital who were public
and semi-private clients, singleton cephalic presentation, gestational age of 35-36 weeks,
no medical complications which would contraindicate the use of ergometrine or increase
risk of bleeding (such as cardiovascular disease, use of heparin and hypertension), low
risk to haemorrhage such as age 35 years or less, parity 5 or less, no previous history of
primary PPH, Hb 11 g/dL or more (IV sample) or 10.6 or more (capillary sample)
Exclusions: women who had hypertension (140/95 or greater), epidural anaesthesia,
antenatal haemorrhage, first stage of labour in excess of 15 hours and operative delivery
were excluded
Interventions IV ergometrine 0.5 mg following the birth of the baby (n = 705) versus no ergometrine
(n = 724)
Outcomes Mean blood loss; blood loss of at least 500 mL and 1000 mL; mean postnatal Hb (48-72
hours); Hb less than 10 g/dL; manual removal of placenta; blood transfusion; elevation
of diastolic blood pressure (> 95 mmHg); eclamptic fit; vomiting; nausea; headache;
atonic haemorrhage requiring IV or IM ergot; length of third stage of labour; after-birth
pain needing IM or oral analgesia
Notes If eligible pregnant women were excluded, the envelope was returned unopened and
reallocated to next batch
Dates of when the studies were conducted: 1 October 1987 and 31 October 1988
Any details of funding sources: Research andDevelopmentTrust of theCoombeHospital
Any declarations of interest among primary researchers: no information of declarations
of interest
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (from correspondence): “random
number tables were used. The first num-
ber was selected from the table by a disin-
terested observer and the numbers were al-
located in blocks of 100 following the se-
quence.”
Comment: randomised
Allocation concealment (selection bias) Low risk Quote (from correspondence): “the en-
velopes remained sealed until the woman
was in the second stage of labour and
the midwife was certain a normal delivery
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Begley 1990 (Continued)
would ensure.”
Comment: adequate concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote (from correspondence): “it was not
possible to blind either women or the clin-
icians as ergometrine given intravenously
causes a strong contraction that is felt and
seen by both parties.”
Comment: intervention or control was not
blinded which is likely to be influenced by
lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote (from correspondence): “The tech-
nicians conducting the haemoglobin esti-
mations were blind to trial allocation.”
Comment: incomplete blinding of out-
come assessment such as mean blood loss
which is likely to be influenced by lack of
blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “same number of participants al-
located and outcomes identified were re-
ported.”
Comment: no missing outcome data
Selective reporting (reporting bias) Low risk It is clear that the published reports include
all expected outcomes specified
Other bias Low risk The study appears to be free of other
sources of bias.
Daley 1951
Methods Randomisation by alternative weekends changing with each team of obstetricians and
midwives No blinding
Participants Eligibility: women having delivered spontaneously of a single fetus after less than 48
hours of labour, parity less than 5 and no antepartum haemorrhage or hydramnios at St
Helier Hospital
Interventions IM ergometrine 0.5mg as soon as the head was crowned (n = 490) versus no ergometrine
(n = 510)
Outcomes Mean blood loss; blood loss of at least 500 mL; retained placenta for 60 min or more;
mean length of third stage of labour
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Daley 1951 (Continued)
Notes 2 women excluded because of traumatic haemorrhage as clinicians felt convinced of the
value of ergometrine. All outcomes were stratified by gravida
Dates of when the studies were conducted: written that “The experiment was stated in
the spring of 1949” but ended period was not written
Any details of funding sources: no details given.
Any declarations of interest among primary researchers: no information of declarations
of interest
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote: “treated cases were divided from
controls by the simple method of the tech-
niques changing with the team of obstetri-
cians on duty. Two teams changed at 9 am
each weekday and worked alternate week-
ends.”
Comment: sequence generated by some
rule based on day of admission
Allocation concealment (selection bias) High risk Participants were assigned based on alter-
nation or rotation.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not blinded or incomplete blinding and
the outcome or outcome measurement is
likely to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not blinded or incomplete blinding and
the outcome or outcome measurement is
likely to be influenced by lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “same number of participants al-
located and outcomes identified were re-
ported.”
Comment: no missing outcome data
Selective reporting (reporting bias) Low risk It is clear that the published reports include
all expected outcomes specified
Other bias Low risk The study appears to be free of other
sources of bias.
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De Groot 1996b
Methods A double-blind multicentre trial with randomisation by computer-generated randomisa-
tion list. Ergometrine and placebo were identical. The boxes of ergometrine and placebo
were numbered by hospital pharmacy
Participants Eligibility: all deliveredwomen in 2 university hospitals (Leiden, Nijmegen), amidwifery
school (Kerkrade) and by independent midwives in the area of the university hospital of
Nijmegen in the study period
Exclusions: refusal to participate, cardiovascular diseases, multiple pregnancies, non-
cephalic presentation, polyhydramnios, tocolysis given 2 hours prior to delivery, antico-
agulant therapy, stillbirth, antepartum haemorrhage, induction or augmentation, oper-
ative vaginal deliveries, anaemia less than 6.8 g, former complications in the third stage
of labour or women who wish natural births
Interventions Total of 367 women were assigned to 2:2:1 of oral ergometrine 0.4 mg (n = 146), oral
placebo tablets (n = 143) and standard IM oxytocin (n = 78) immediately after birth
Outcomes Mean blood loss measured by gravimetric method; blood loss of at least 500 mL and
1000 mL; removal of placenta; requiring blood transfusion; use of further oxytocics;
length of third stage
Notes Data for length of third stage were presented as mean only, no standard deviation given
Dates of when the studies were conducted: July 1993 to July 1994
Any details of funding sources: no details given
Any declarations of interest among primary researchers: no information of declarations
of interest
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “the hospital pharmacy of the
Univeristy of Nijmegen supplied num-
bered boxes containing 0.4mg ergometrine
tablets, placebo tablets or 5 IU oxytocin ac-
cording a computer-generated randomisa-
tion list.”
Comment: randomised
Allocation concealment (selection bias) Low risk Quote: “the hospital pharmacy of the Uni-
veristy of Nijmegen supplied numbered
boxes.... randomisation list. Care was taken
that no difference could be seen or heard
between the packages of the ergometrine/
placebo tablets and the oxytocin ampoules.
”
Comment: adequate concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “the hospital pharmacy of the
Univeristy of Nijmegen supplied num-
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De Groot 1996b (Continued)
bered boxes containing 0.4mg ergometrine
tablets, placebo tablets or 5 IU oxytocin ac-
cording a computer-generated randomisa-
tion list.”
Comment: a placebo tablet of ergometrine
tablet was used.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “the hospital pharmacy of the
Univeristy of Nijmegen supplied num-
bered boxes containing 0.4mg ergometrine
tablets, placebo tablets or 5 IU oxytocin ac-
cording a computer-generated randomisa-
tion list.”
Comment: a placebo tablet of ergometrine
tablet was used.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “same number of participants al-
located and outcomes identified were re-
ported.”
Comment: no missing outcome data
Selective reporting (reporting bias) Low risk It is clear that the published reports include
all expected outcomes specified
Other bias Low risk The study appears to be free of other
sources of bias.
Howard 1964
Methods A double-blind trial with simple randomisation. The vials were coded and identical in
appearance
Participants Eligibility: all vaginally delivered women at the University of Iowa Hospital
Exclusion: women delivered by caesarean section
Interventions 3 groups of comparisons: IV methylergonovine maleate 0.2 mg (n = 505), IV 0.9%
sodium chloride (n = 475) and oxytocin (n = 479) following placental delivery
Outcomes Blood loss of at least 500 mL; elevation of systolic or diastolic blood pressure greater
than 10 mmHg; need further treatment (vigorous uterine massage, IV or IM methyler-
gonovine and/or oxytocin)
Notes Elevation of blood pressure was stratified by normotensive or hypertensive and pre-
eclamptic women
Dates of when the studies were conducted: August 1962 to July 1963
Any details of funding sources: Public Health Service Grant No. GM-08943-02 and No.
AO-00555-03
Any declarations of interest among primary researchers: no information of declarations
of interest
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Howard 1964 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “patients were randomly selected
for 1 of 3 study groups.”
Comment: insufficient information about
the sequence generation process to permit
judgement of “Yes” or “No”
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment of “Yes” or “No” as the method of
concealment is not described in sufficient
detail to allow a definite judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “a double-blinded technique was
used..... The vials were identical in appear-
ance and the contents were not known un-
til completion of the study.”
Comment: blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “a double-blinded technique was
used..... The vials were identical in appear-
ance and the contents were not known un-
til completion of the study.”
Comment: blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “2% to 8% of recruited subjects
were missing at measuring outcomes.”
Comment: for dichotomous outcome data,
the proportion of missing outcomes com-
pared with observed events risk not enough
to have a clinically relevant impact on the
intervention effect estimate
Selective reporting (reporting bias) Low risk It is clear that the published reports include
all expected outcomes specified
Other bias Low risk The study appears to be free of other
sources of bias.
Ilancheran 1990
Methods Women were equally divided into 4 groups on a random basis. No blinding
Participants Eligibility: 20 consecutive women with spontaneous labour, between 38-42 weeks who
had normal vertex delivery
Exclusion: no details given
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Ilancheran 1990 (Continued)
Interventions 4 groups of comparison: no oxytocics in the third stage (n = 5), IV syntocinon (n = 5)
, IV syntometrine (n = 5) and IV ergometrine (n = 5) when anterior shoulder of baby
was delivered. All the drugs were given intravenously and in standard doses
Outcomes Serum levels of prostaglandins in the third stage of labour; postpartum haemorrhage at
least 500 mL
Notes In the results, we could not identify the actual figures of mean and standard deviation
of prostaglandin levels. Postpartum haemorrhage was not defined for outcome in the
methods but postpartum haemorrhage (600 mL) was found in 1 woman to whom
ergometrine was given. No haemorrhage found in other groups. The correspondence
author was contacted and no available data existed as the study was conducted in past
30 years
Dates of when the studies were conducted: no details given
Any details of funding sources: no details given
Any declarations of interest among primary researchers: no information of declarations
of interest
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “The patients were equally divided
on a random basis”
Comment: insufficient information about
the sequence generation process to permit
judgement of “Yes” or “No”
Allocation concealment (selection bias) Unclear risk Methods not mentioned
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not possible to blind this type of interven-
tion when not placebo-controlled
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not possible to blind this type of interven-
tion when not placebo-controlled
Outcome assessors not mentioned
Incomplete outcome data (attrition bias)
All outcomes
High risk Number of participants in outcome iden-
tified were not reported
Selective reporting (reporting bias) High risk Postpartum haemorrhage not prespecified
in methods section but reported
Other bias Unclear risk Baseline characteristics not listed, difficult
to identify other sources of bias
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Jolivet 1978
Methods Women were randomised into 2 groups. No blinding.
Participants Eligibility: full-term healthy women at the first 6 days of postpartum
Exclusion: no details given
Interventions 2 groups of comparison: no ergot at delivery or in the following 6 days (n = 28) and IM
0.2 mg methylergobasine maleate (Methergine) immediately after delivery followed by
3 x 1 mg tablets of ergotamine tartrate (Gynergen) by mouth daily (n = 30)
Outcomes Newborn birthweight and quantity of milk in 24 hours were measured
Notes A paper was published in French and Anna Cuthbert, Research Associate at Cochrane
Pregnancy and Childbirth, University of Liverpool, helped with assessing risk of bias
and data extraction
Dates of when the studies were conducted: no details given
Any details of funding sources: no details given
Any declarations of interest among primary researchers: no information of declarations
of interest
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk 2 groups were formed at random - no fur-
ther detail given
Allocation concealment (selection bias) Unclear risk Methods not mentioned
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not possible to blind this type of interven-
tion when not placebo-controlled
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not possible to blind this type of inter-
vention when not placebo-controlled Out-
come assessors not mentioned
Incomplete outcome data (attrition bias)
All outcomes
High risk Neonatal denominators not included in ta-
bles
Selective reporting (reporting bias) Low risk 2 outcomes prespecified in methods sec-
tion, and reported
Other bias Unclear risk Baseline characteristics not listed, difficult
to identify other sources of bias
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Kerekes 1979
Methods Simple randomisation into 3 comparison groups without concealment or blinding
Participants Eligibility: womenwith spontaneous uncomplicated vaginal deliveries atKorvinHospital
Exclusions: no details given
Interventions 3 groups of comparisons were IV ergometrine 0.2mg (n = 50), no treatment (n = 43) and
intramyometrial prostaglandins (PGF2alpha) 1 mg (n = 47) after clamping of umbilical
cord
Outcomes Mean blood loss measured by cylinder after the collection of blood from container;
maternal Hb concentration at 48 hours postpartum; duration of third stage of labour;
uterine subinvolution at routine follow-up; postpartum febrile morbidity
Notes No data shown for mean blood loss or maternal Hb
Dates of when the studies were conducted: no details given
Any details of funding sources: no details given
Any declarations of interest among primary researchers: no information of declarations
of interest
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “three groups were formed by as-
signing the patients randomly to no treat-
ment and to treatment with PGF2α and
ergometrin.”
Comment: insufficient information about
the sequence generation process to permit
judgement of “Yes” or “No”
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment of “Yes” or “No” as the method of
concealment is not described in sufficient
detail to allow a definite judgement
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not blinded or incomplete blinding and
the outcome or outcome measurement is
likely to be influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not blinded or incomplete blinding and
the outcome or outcome measurement is
likely to be influenced by lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “same number of participants al-
located and outcomes identified were re-
ported.”
Comment: no missing outcome data.
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Kerekes 1979 (Continued)
Selective reporting (reporting bias) Low risk It is clear that the published reports include
all expected outcomes specified
Other bias Low risk The study appears to be free of other
sources of bias.
McGinty 1956
Methods Simple randomisation into 4 comparison groups.
Participants Eligibility: women delivering vaginally at the Creighton Memorial St Joseph’s Hospital
and Bramwell Booth Memorial Hospital. Exclusions: no details provided
Interventions 4 groups of comparisons were IV methergine 0.2 mg (n = 50), ergonovine 0.2 mg (n
= 50), pitocin 5 units (n = 50) and normal saline 1 mL (n = 50) after birth of anterior
shoulder
Outcomes Blood transfusion, elevation of blood pressure (increase of systolic blood pressure 20 or
more) and severe elevation (systolic blood pressure more than 170); vomiting; nausea;
headache; eclamptic fit
Notes Elevation of blood pressure were stratified by normotensive or hypertensive women. 5
severe PPH (no criteria shown) were found in the placebo group
• Dates of when the studies were conducted: no details given
• Any details of funding sources: no details given
• Any declarations of interest among primary researchers: no information of
declarations of interest
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “these cases were picked at random
manner.”
Comment: insufficient information about
the sequence generation process to permit
judgement of “Yes” or “No”
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment of “Yes” or “No” as the method of
concealment is not described in sufficient
detail to allow a definite judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “the series has been broken down
into four groups:........... of methergine
intravenously;...... of ergonovine intra-
venously;..... of pitocin intravenously and
five units intramuscularly.... the control
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McGinty 1956 (Continued)
group ... one cubic centimeter of normal
saline intravenously.”
Comment: insufficient information to per-
mit judgement of “Yes” or “No”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “the series has been broken down
into four groups:........... of methergine
intravenously;...... of ergonovine intra-
venously;..... of pitocin intravenously and
five units intramuscularly.... the control
group ... one cubic centimeter of normal
saline intravenously.”
Comment: insufficient information to per-
mit judgement of “Yes” or “No”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “same number of participants al-
located and outcomes identified were re-
ported.”
Comment: no missing outcome data
Selective reporting (reporting bias) Low risk It is clear that the published reports include
all expected outcomes specified
Other bias Low risk The study appears to be free of other
sources of bias.
Hb: haemoglobin
IM: intramuscular
IV: intravenous
min: minute(s)
PPH: postpartum haemorrhage
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Adhikari 2007 Comparisons of 0.2 mg IM methylergometrine and 10 IU IM oxytocin
Amant 1999 Comparisons of oral misoprostol and IV methylergometrine included in previous Cochrane Review
Badhwar 1991 Management with nipple stimulation
Barbaro 1961 Comparisons of IM syntometrine and ergometrine included in previous Cochrane Review
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(Continued)
Baumgarten 1983 Comparisons of ergometrine, oxytocin and sulprostone on uterine contractility by intra-catheter pressure
excluded in previous Cochrane Review due to no possible outcomes
Bonham 1963 Comparisons of syntometrine, ergometrine and ergometrine plus hyaluronidase included in previous
Cochrane Review
Boopathi 2014 Comparisons of 0.2 mg IV methylergometrine and 10 IU IM oxytocin
Caliskan 2002 Comparisons ofmisoprostol plus oxytocin,misoprostol, oxytocin andoxytocin plus ergometrine included
in previous Cochrane Review
Carpén 1968 Comparisons of IM OCM 505 and IV methergine
Chatterjee 2000 No data can be extracted, excluded in previous Cochrane Review
Chukudebelu 1963 Not randomised controlled trial comparing 0.5 U of syntocinon plus 0.5 mg of ergometrine, 0.5 mg of
ergometrine and 1 mg of ergometrine
Dhananjaya 2014 Comparison of 0.2 mg IM methylergometrine and 10 IU IM oxytocin
Diab 1999 Comparisons of misoprostol and ergometrine excluded in previous Cochrane Review
Docherty 1981 Data were not suitable for extraction and failed contact with author excluded in previous 2 Cochrane
Reviews
Dweck 2000 Participants were women who underwent caesarean section and received 0.2 mg of methergine orally
every 6 hours until hospital discharge with the first dose being within the first 6 hours after caesarean
section. The outcome was diagnosed endometritis
EudraCT2010-01980-42 Only a protocol registered in the EU clinical trial register on 13 July 2010 was found but no results and
publication were available. It was not possible to identify a contact person and so we were unable to
contact anyone for any further details about the results of the study
Ezeama 2014 Comparison of 0.5 mg IM ergometrine and 10 IU IM oxytocin
Fawzy 2012 Comparison of 10 mL IV ergotmetrine and 200 mcg rectal or sublingual tablet of misoprostol
Forster 1957 Not randomised controlled trial comparing 0.2 mg of methergine versus ergometrine given IV immedi-
ately after the delivery of the baby for 24 weeks and for next 8 weeks, 0.2mg ofmethergine or ergometrine
given additionally by IM injection after the expression of the placenta
Francis 1965a Comparisons of syntometrine before placental delivery and ergometrine after placental delivery excluded
in previous Cochrane Review
Francis 1965b Comparisons of IM syntometrine and ergometrine included in previous Cochrane Review
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(Continued)
Friedman 1957 Not randomised controlled trial comparing no medication as a control, 10 units of oxytocin IM, 0.
2 mg of ergonovine maleate IM or IV, 0.2 mg of methylergonovine tartrate IM or IV and 1 mg of
dihydroergotamine methanesulfonate IM after delivery of placenta
Fugo 1958 Comparisons of IV oxytocin, syntometrine, U3772 and ergometrine included in previous Cochrane
Review
Groeber 1960 Comparisons of 0.2 mg of methergine and 0.2 mg of ergonovine IV after delivery of placenta
Gupta 2014 Comparisons of 0.2 mg IM methoergin and 125 mcg IM carboprost
Hacker 1979 Not randomised controlled trial comparing no drug as a control, syntometrine (combining 5 U of
oxytocin and 0.5 mg of ergometrine maleate) IM and 0.5 mg of ergometrine maleate IV
Huh 2004 Comparisons of oxytocin administered before and after placental delivery excluded in previous Cochrane
Review due to comparison of oxytocin with time difference
Is 2012 Comparisons of IM ergometrine and 400 mcg rectal misoprostol
Jago 2007 Comparisons of IM 0.5 mg of ergometrine and IV 10 IU of oxytocin
Kemp 1963 Not randomised controlled trial comparing syntometrine (combining 5 IU of syntocinon and 0.5 mg of
ergometrine) IM with 0.5 mg of ergometrine IM
Khan 1995 Comparisons of IM syntometrine and oxytocin included in previous Cochrane Review
Kikutani 2003 Comparisons of oxytocin and ergometrine on epidural pressure
Lam 2004 Comparisons of sublingual misoprostol and IV syntometrine
Lamont 2001 Comparisons of syntometrine and prostaglandin
Mitchell 1993 Comparisons of syntometrine and oxytocin included in previous Cochrane Review
Moir 1979 Comparisons of 0.5 mg of ergometrine and 10 IU of oxytocin given at the time of delivery of anterior
shoulder
Moodie 1976 Comparisons of IV 0.5 mg of ergometrine and IV 5 IU of oxytocin
Moore 1956 Not randomised controlled trial comparing 0.2 mg of ergonovine maleate and 0.2 mg of methyler-
gonovine tartrate IV after expulsion of placenta
Nieminen 1963 Comparisons of ergometrine, syntometrine and oxytocin included in previous Cochrane Review
Orji 2008 Comparisons of 0.25 mg of ergometrine and 10 IU oxytocin IV at the delivery of anterior shoulder of
the baby
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(Continued)
Patil 2013 Comparisons of 0.2 mg IV methylergometrine and 600 mcg oral tablet misoprostol
Paull 1977 Comparisons of 0.25 mg and 0.5 mg of ergometrine maleate IV after completion of second stage of
labour
Pei 1996 Not randomised controlled trial and no outcomes of interest comparing oxytocin and ergotocin on
postpartum lactation
Penaranda 2002 Comparisons of sublingual misoprostol, oxytocin and methylergometrine included in previous Cochrane
Review
Rajwani 2000 No data can be extracted, excluded in previous Cochrane Review
Ramesh 1983 Not randomised controlled trial comparing 0.5 mg of PGE2 intramyometrial at the fundus of the uterus
at the time of crowning of fetal head and 0.25 mg of methylergotamine maleate
Reddy 2001 Comparisons of 0.2 mg of methylergometrine IV at the time of anterior shoulder delivery, 10 IU of
oxytocin diluted with 10 mL of normal saline via umbilical cord immediately after clamping the cord
and IM 250 mg of carboprost with the delivery of anterior shoulder of the baby
Rooney 1985 Quasi-randomised controlled trial using odd-even cases comparing syntometrine with the delivery of
anterior shoulder IM and no syntometrine
Saito 2007 Quasi-randomised controlled trial (samples were allocated using weekly or monthly as determined by
each hospital in alternate shifts) comparing 5 IU of oxytocin and 0.2 mg of methylergometrine IM
administered shortly after delivery of the baby
Sharma 2014 Not randomised controlled trial comparing 0.2 mg IV methylergometrine and 10 IU IV oxytocin and
600 mcg sublingual misoprostol
Shrestha 2008 Comparisons of 0.2 mg IM methergine Intramyometrial 250 mcg 15-methyl PGF2a and IM 250 mcg
15-methyl PGF2a
Singh 2009 Comparisons of sublingual 400 microgram and 600 microgram of misoprostol, 5 IU of oxytocin IV and
200 microgram of methylergometrine IV at the delivery of anterior shoulder of the baby
Soiva 1964 Comparisons of IV methylergometrine and IM oxytocin included in previous Cochrane Review
Sorbe 1978 Not randomised controlled trial comparing 0.2 mg of ergometrine, 10 IU of oxytocin IV after delivery
of anterior shoulder and control group which was not described how to select
Stearn 1963 Comparisons of syntometrine and ergometrine excluded in previous Cochrane Review due to allocation
Symes 1984 Comparisons of oxytocin and oxytocin plus ergometrine excluded in previous Cochrane Review due to
no clinical outcomes
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(Continued)
Terry 1970 Quasi-randomised controlled trial comparing IM syntometrine (0.5 mg of ergometrine and 5 IU of
oxytocin) at the delivery of anterior shoulder with IM syntometrine with free bleeding. Outcome of
interest was fetal cells in maternal blood. The comparison group contained another uterotonic and so
this is not eligible for inclusion
Thilaganathan 1993 Comparison of 1 mL of syntometrine after the delivery of baby and no drug
Thornton 1988 Quasi-randomised controlled trial comparing IM oxytocin on the delivery of anterior shoulder and no
treatment
Vaughan 1974 Comparisons of syntometrine and oxytocin excluded in previous Cochrane Review due to 1 outcome
on central venous pressure
Vimala 2004 Comparisons of sublingual misoprostol and IM methylergometrine
Weiss 1975 Quasi-randomised controlled trial comparing 0.2 mg of methylergonovine maleate after delivery of
placenta and 1 mL of normal saline IM. Only serum prolactin before and after 80-90 min after injection
was measured. Excluded because none of the outcomes of the review were measured
Yardim 1967 Comparisons of oxytocin plus ergometrine and no drug
Yuen 1995 Comparisons of syntometrine and oxytocin included in previous Cochrane Review
IM: intramuscular
IV: intravenous
IU: international unit(s)
U: unit(s)
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D A T A A N D A N A L Y S E S
Comparison 1. Ergot alkaloids (any route of administration) versus no uterotonic agents
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mean blood loss (mL) 3 2718 Mean Difference (IV, Fixed, 95% CI) -80.52 [-96.39, -64.
65]
2 Estimated or measured blood
loss of at least 500 mL
5 3708 Risk Ratio (M-H, Random, 95% CI) 0.52 [0.28, 0.94]
3 Estimated or measured blood
loss of at least 1000 mL
2 1718 Risk Ratio (M-H, Random, 95% CI) 0.32 [0.04, 2.59]
4 Maternal haemoglobin
concentration at 24 to 48 hours
postpartum (g/dL)
1 1429 Mean Difference (IV, Fixed, 95% CI) 0.5 [0.38, 0.62]
5 Blood transfusion 3 1868 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.08, 1.40]
6 Use of therapeutic uterotonics 3 2698 Risk Ratio (M-H, Random, 95% CI) 0.37 [0.15, 0.90]
7 Length of third stage of labour
(minutes)
3 2522 Mean Difference (IV, Random, 95% CI) -1.70 [-3.33, -0.06]
8 Retained placenta or manual
removal of placenta, or both
3 2718 Risk Ratio (M-H, Random, 95% CI) 3.86 [0.36, 41.78]
9 Vomiting 2 1579 Risk Ratio (M-H, Random, 95% CI) 6.82 [0.37, 126.26]
10 Nausea 2 1579 Risk Ratio (M-H, Random, 95% CI) 8.63 [0.26, 284.55]
11 Elevation of blood pressure 3 2559 Risk Ratio (M-H, Random, 95% CI) 2.60 [1.03, 6.57]
12 Pain after birth requiring
analgesia (not prespecified)
1 1429 Risk Ratio (M-H, Fixed, 95% CI) 2.53 [1.34, 4.78]
13 Headache (not prespecified) 2 1579 Risk Ratio (M-H, Fixed, 95% CI) 3.93 [0.51, 30.50]
14 Eclamptic fit (not prespecified) 2 1579 Risk Ratio (M-H, Fixed, 95% CI) 3.34 [0.38, 29.43]
15 Uterine subinvolution at
routine follow up (not
prespecified)
1 93 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.56, 1.32]
16 Postpartum febrile morbidity
(not prespecified)
1 93 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.34, 3.15]
17 Postnatal haemoglobin < 10 g/
dL (not prespecified)
1 1429 Risk Ratio (M-H, Fixed, 95% CI) 0.30 [0.14, 0.67]
Comparison 2. Intravenous/intramuscular ergot alkaloids versus no uterotonic agents
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mean blood loss (mL) 2 2429 Mean Difference (IV, Fixed, 95% CI) -81.75 [-97.88, -65.
61]
2 Estimated or measured blood
loss of at least 500 mL
4 3419 Risk Ratio (M-H, Random, 95% CI) 0.41 [0.22, 0.75]
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3 Estimated or measured blood
loss of at least 1000 mL
1 1429 Risk Ratio (M-H, Fixed, 95% CI) 0.09 [0.01, 0.72]
4 Maternal haemoglobin
concentration at 24 to 48 hours
postpartum (g/dL)
1 1429 Mean Difference (IV, Fixed, 95% CI) 0.5 [0.38, 0.62]
5 Blood transfusion 2 1579 Risk Ratio (M-H, Fixed, 95% CI) 0.34 [0.05, 2.16]
6 Use of therapeutic uterotonics 2 2409 Risk Ratio (M-H, Random, 95% CI) 0.25 [0.10, 0.66]
7 Length of third stage of labour
(minutes)
3 2522 Mean Difference (IV, Random, 95% CI) -1.70 [-3.33, -0.06]
8 Retained placenta or manual
removal of placenta, or both
2 2429 Risk Ratio (M-H, Random, 95% CI) 3.75 [0.14, 99.71]
9 Vomiting 2 1579 Risk Ratio (M-H, Random, 95% CI) 6.82 [0.37, 126.26]
10 Nausea 2 1579 Risk Ratio (M-H, Random, 95% CI) 8.63 [0.26, 284.55]
11 Elevation of blood pressure 3 2559 Risk Ratio (M-H, Random, 95% CI) 2.60 [1.03, 6.57]
12 Pain after birth requiring
analgesia (not prespecified)
1 1429 Risk Ratio (M-H, Fixed, 95% CI) 2.53 [1.34, 4.78]
13 Headache (not prespecified) 2 1579 Risk Ratio (M-H, Fixed, 95% CI) 3.93 [0.51, 30.50]
14 Eclamptic fit (not prespecified) 2 1579 Risk Ratio (M-H, Fixed, 95% CI) 3.34 [0.38, 29.43]
15 Uterine subinvolution at
routine follow up (not
prespecified)
1 93 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.56, 1.32]
16 Postpartum febrile morbidity
(not prespecified)
1 93 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.34, 3.15]
17 Postnatal haemoglobin < 10 g/
dL (not prespecified)
1 1429 Risk Ratio (M-H, Fixed, 95% CI) 0.30 [0.14, 0.67]
Comparison 3. Oral ergot alkaloids versus no uterotonic agents
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mean blood loss (mL) 1 289 Mean Difference (IV, Fixed, 95% CI) -44.0 [-132.08, 44.
08]
2 Estimated or measured blood
loss of at least 500 mL
1 289 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.72, 1.29]
3 Estimated or measured blood
loss of at least 1000 mL
1 289 Risk Ratio (M-H, Random, 95% CI) 0.73 [0.36, 1.50]
4 Blood transfusion 1 289 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.03, 3.10]
5 Use of therapeutic uterotonics 1 289 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.47, 1.34]
6 Retained placenta or manual
removal of placenta, or both
1 289 Risk Ratio (M-H, Random, 95% CI) 4.90 [0.24, 101.14]
7 Elevation of blood pressure 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Pain after birth requiring
analgesia (not prespecified)
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Comparison 4. Sensitivity analysis based on trial quality comparing ergot alkaloids (any routes) and no uterotonic
agents
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mean blood loss (mL) 2 1718 Mean Difference (IV, Fixed, 95% CI) -84.07 [-102.47, -
65.67]
2 Estimated or measured blood
loss of at least 500 mL
3 2698 Risk Ratio (M-H, Random, 95% CI) 0.44 [0.16, 1.24]
3 Length of third stage of labour
(minutes)
2 1522 Mean Difference (IV, Random, 95% CI) -1.07 [-2.32, 0.19]
4 Retained placenta or manual
removal of placenta, or both
2 1718 Risk Ratio (M-H, Random, 95% CI) 12.79 [2.40, 68.19]
WH A T ’ S N E W
Last assessed as up-to-date: 19 September 2017.
Date Event Description
19 September 2017 New search has been performed Search updated. We assessed 12 new reports (11 stud-
ies) and all were excluded. We reassessed two previ-
ously excluded studies and included them in this up-
date (Ilancheran 1990; Jolivet 1978). Therefore, this
review now includes eight randomised controlled tri-
als. The comparisons have been restructured so that
they are not subgrouped by route, but different routes
are analysed in separate comparisons. We have pro-
duced three ’Summary of findings’ tables for this up-
date
19 September 2016 New citation required but conclusions have not
changed
The conclusions remain unchanged.
H I S T O R Y
Protocol first published: Issue 3, 2005
Review first published: Issue 2, 2007
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Date Event Description
30 April 2011 New search has been performed Search updated. Three new reports identified and ex-
cluded (Kemp 1963; Orji 2008; Singh 2009). Conclu-
sions not changed.
7 September 2008 New search has been performed Search updated. Three new studies identified and ex-
cluded (Jago 2007; Moodie 1976; Saito 2007) and
another report of the Thornton 1988 excluded study
added.
4 April 2008 Amended Converted to new review format.
12 February 2007 New citation required and conclusions have changed Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
Tippawan Liabsuetrakul (TL)
TL was involved in all parts of preparing the review, and wrote the first and final draft of the review. For the 2011 update, TL
assessed the full texts of the additional three references, identified from the updated search, against the criteria for inclusion; appraised
methodological quality of all included studies; and prepared the updated review. For the 2017 update, TL assessed all 12 new reports
from the updated search, updated the review in accordance with the new format and prepared the final updated review.
Krantarat Peeyananjarassri (KP)
KP was involved in assessing the included or excluded studies, and commented on the first draft of the review. For the 2011 update, KP
assessed the full texts of the additional three references, identified from the updated search, against the criteria for inclusion; appraised
methodological quality of all included studies; and approved the final version of the updated review. For the 2017 update, KP assessed
all 12 new reports from the updated search and approved the final version of the updated review.
Thanapan Choobun (TC)
TC was involved in assessing the quality of included studies and extracting the data. TC commented on the first draft of the review.
For the 2011 and 2017 update, TC approved the final version of the updated review.
Monir Islam (MI)
MI commented on the draft review. For the 2011 and 2017 update, MI approved the final version of the updated review.
D E C L A R A T I O N S O F I N T E R E S T
Tippawan Liabsuetrakul: none known.
Thanapan Choobun: none known.
Krantarat Peeyananjarassri: none known.
Q Monir Islam: none known.
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S O U R C E S O F S U P P O R T
Internal sources
• Faculty of Medicine, Prince of Songkla University, Thailand.
External sources
• Thailand Research Fund (Distinguished Research Professor Award), Thailand.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We listed 11 maternal outcomes related to both efficacy and safety, and four neonatal outcomes, in the original protocol. However,
six additional outcomes were identified in the review published in 2007 and 2008. In this updated version, we divided the outcomes
into primary and secondary outcomes. We chose the outcomes which directly represented “haemorrhage” as the primary outcomes and
considered all other maternal and neonatal outcomes as secondary outcomes. We changed the outcome “third stage of labour lasting
more than 30 minutes” to “length of third stage of labour (minutes)”.
For this 2017 update, we added an additional search of ClinicalTrials.gov and theWHO International Clinical Trials Registry Platform
(ICTRP). Two excluded studies in the previous review were included (Ilancheran 1990; Jolivet 1978). They had previously been
excluded due to not reporting outcomes of the review.
In previous version of this review, there was one comparison which was subgrouped by route of administration (intravenous/intramus-
cular and oral). These have now been separated out into three separate comparisons in this update:
1. ergot alkaloids (any route of administration) versus no uterotonic agents
2. intravenous/intramuscular ergot alkaloids versus no uterotonic agents
3. oral ergot alkaloids versus no uterotonic agents
The original prespecified subgroup analyses were:
• risk of having a postpartum haemorrhage: high risk versus low risk;
• route of administration of ergot alkaloids: intramuscular or intravenous compared with oral route.
In this update (2017), they have been amended slightly to:
1. use of ergot alkaloids with or without active management of third stage of labour;
2. use of ergot alkaloids before or after placental delivery;
3. use of ergot alkaloids in different doses.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Labor Stage, Third; Ergot Alkaloids [administration & dosage; ∗therapeutic use]; Injections, Intramuscular; Injections, Intravenous;
Postpartum Hemorrhage [∗prevention & control]; Randomized Controlled Trials as Topic
MeSH check words
Female; Humans; Pregnancy
54Prophylactic use of ergot alkaloids in the third stage of labour (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
